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Abstract
The purpose of this study was to determine whether there is evidence to support conducting a
larger randomized control trial (RCT) to compare the non-operative treatment of Achilles
tendon (AT) ruptures with or without Autologous Conditioned Plasma (ACP®). Twenty-four
patients were randomized to receive an ACP® or saline injection within seven days and
again at two weeks post-rupture. Tendon healing was longitudinally evaluated using
ultrasound (US) and magnetic resonance imaging (MRI). Functional and patient-reported
quality of life measures were also assessed. A small sample size limited our ability to detect
statistically significant differences. The mean rankings of healing were slightly higher in the
ACP® group at most time points for MRI and US. Functional and patient-reported outcomes
were also slightly higher in the ACP® group at most time points. The consistency of these
preliminary results suggests that there is evidence to support conducting a larger RCT.
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Chapter 1

1

Introduction

Rupture of the Achilles tendon (AT) is one of the most common tendinous injuries within
the adult population. Throughout the last two decades, the incidence of AT rupture has
significantly increased as a result of more adults participating in high-demand sports1–3.
Tissue healing and regeneration in the AT is a slow process which results in a slow return
of normal function. Management of AT ruptures can be broadly classified into operative
and non-operative treatment, although there is considerable debate regarding which
treatment is optimal as each has unique advantages and disadvantages. In the past,
operative treatment has been associated with a lower risk for re-rupture at the expense of
a higher risk of surgical and post-surgical complications, whereas non-operative
treatment is associated with a lower risk of complications but a higher risk for re-rupture.
However, in 2010, Willits et al4 published the results of a randomized control trial that
reported similar functional and patient-reported outcomes, as well as similar re-rupture
rates between operatively and non-operatively treated patients. They hypothesized that
the similarity in re-rupture rates was attributed to the early mobilization rehabilitation
protocol. A recent meta-analysis of the literature by Soroceanu et al (2012)5 yielded
similar conclusions regarding re-rupture rates when the non-operative management
included early mobilization.
Platelet-rich plasma (PRP) is a generic term describing products that contain aboveaverage amounts of platelets in a small volume of plasma. PRP has been used
increasingly for the treatment of various orthopedic injuries6. The physiological rationale
for concentrating platelets at a site of injury is to optimize the healing environment,
although there is no clear indication for the clinical efficacy of PRP.
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One limitation of PRP research is the lack of standardization of the intervention,
preparation methods and contents of the PRP. Different preparation methods yield PRP
samples with different platelet concentrations and leukocyte concentrations. Some
samples also require an exogenous platelet activator. To determine the most effective
method of PRP preparation and administration, this information must be reported and
more head to head comparisons evaluated7.
To date, there has been one study that has examined the effectiveness of ACP® for the
non-operative management of AT ruptures8. The results of this study did not support a
measurable clinical or functional benefit of ACP® when compared to non-operative
management without ACP®. The notable limitations of this study include the use of a
retrospective control group, and an ACP® injection period spanning 14 days from the
time of rupture. There is anecdotal evidence that suggests that earlier PRP injections (i.e.
at the time of surgery, less than seven days post-rupture) may yield more favorable
functional and histochemical results9–12. This may be related to the contents of the PRP
and because the PRP may be most effective during the inflammatory phase of tendon
healing. One of the significant characteristics of this phase of healing is the activation of
platelets at the site of tendon injury, which can last up to seven days post-injury13–15.
Thus, the purpose of this randomized control trial is to determine whether ACP®
injections within seven days post AT rupture and again at two weeks post-rupture
demonstrate better tendon healing on imaging (i.e. ultrasound and magnetic resonance
imaging), better functional outcomes, and more favorable patient-reported outcomes than
patients with AT rupture who receive saline injections at the same time points. Should
this study demonstrate that earlier ACP® injections yield more favorable outcomes, then
a larger RCT would be warranted.
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Chapter 2

2

Literature Review

2.1 Anatomy of the Achilles Tendon
A tendon is a type of connective tissue that is interposed between muscle and bone.
Tendons are comprised primarily of collagen (specifically type I collagen) and elastin
embedded in a proteoglycan-water matrix, with collagen and elastin accounting for 6580% and 2-4% of the tendon’s dry mass, respectively16. The fibro-elastic nature of the
tendon makes it resistant to mechanical loads, thus allowing the force generated within
the muscle to be transmitted to bone, ultimately enabling movement about a joint16.
The Achilles tendon (AT) is the thickest and strongest tendon in the human body17,18.
The distal aspects of the gastrocnemius and soleus muscles merge to form the origin of
the AT (Figure 1). The gastrocnemius is a fusiform muscle formed by medial and lateral
heads originating from the distal femoral condyles19, and is the most superficial muscle in
the dorsal aspect of the lower leg19,20. The soleus is deep to the gastrocnemius and can be
described as a pennate muscle originating from a fibrous arch between the tibia and fibula
in the middle third of the lower leg and from the posterior surface of the head of the
fibula19,21. The gastrocnemius and soleus form the triceps surae, which acts to plantarflex
the ankle joint via the AT20.
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Figure 1 Calf muscles and Achilles tendon
Medical Illustration Copyright © 2015 Nucleus Medical Media

The average length of the AT is 15 cm, but can range from 11 to 26 cm20,22,23. At its
proximal origin the AT is rounded, but flattens out at the distal insertion. The mean width
of the AT is 6.8 cm (4.5-8.6 cm) at its origin and gradually decreases distally. The AT
inserts at the midpoint of the posterior surface of the calcaneus, with a mean width of 3.4
cm (2.0-4.8 cm)20,23.

2.2
2.2.1

Achilles Tendon Rupture
Epidemiology

Although the AT is the most commonly ruptured tendon in the body24, few studies have
examined the epidemiology of AT ruptures. Leppilahti et al (1996)25 detailed the
incidence of AT rupture in Oulu, Finland from 1979 to 1994. During this 16-year period,
there were 110 ruptures. The incidence increased from two ruptures per 105 individuals

5

between 1979 to 1986, to 12 ruptures per 105 individuals between 1987-1994.The peak
age-specific annual rupture incidence was in individuals aged 30-39 (r=0.74, p<0.001).
The rupture ratio of males to females was 5.5:1. Additionally, 81% of ruptures occurred
during sporting activities with 88% of those occurring during ball games.
Similarly, Möller	
  et	
  al	
  (1996)	
  studied	
  the	
  incidence	
  of	
  AT	
  rupture	
  in	
  Malmö,	
  Sweden	
  
from	
  1987-‐1991.	
  They	
  reported	
  153	
  diagnosed	
  cases	
  during	
  this	
  span.	
  The	
  average	
  
annual	
  age	
  incidence	
  per	
  105	
  was	
  calculated	
  for	
  each	
  10-‐year	
  age	
  interval.	
  The	
  
highest	
  incidence	
  was	
  found	
  in	
  the	
  30-‐39	
  year	
  age	
  group	
  with	
  an	
  incidence	
  of	
  30.4	
  
per	
  105	
  individuals.	
  There	
  were	
  significantly	
  more	
  men	
  (132)	
  than	
  women	
  (21)	
  that	
  
were	
  diagnosed	
  with	
  AT	
  rupture.	
  Sports	
  injuries	
  (98)	
  were	
  more	
  common	
  than	
  
other	
  injuries	
  (55),	
  with	
  badminton,	
  soccer,	
  and	
  tennis	
  being	
  the	
  sport	
  most	
  often	
  
leading	
  to	
  AT	
  rupture.	
  	
  
A literature review conducted by Leppilahti & Orava (1998)1 found similar results to the
previous study conducted by Leppilahti et al (1996)25 with respect to the average rupture
ratio of males to female (6:1) and the age of peak incidence (30-40). Additionally, they
found that an average of 75% of AT ruptures were sports-related, especially recreational
sports demanding sudden acceleration and jumping. Within this group, an average of 8 to
20% of AT ruptures occurred in elite athletes, 75% in recreational athletes, and 10 to
12% did not take part in any sports.
Suchak et al (2005)26 retrospectively examined the incidence of AT rupture in the North
American population, specifically in Edmonton, Canada. They found a comparable
incidence (8.3 ruptures per 105 individuals) to those reported in European communities
(range 6 to 37 per 105 individuals). The rupture ratio of males to females was 4:1, with
the mean age of males being 40.6 years and females being 44.5 years. The 30-39 and 4049 year old age groups were most frequently associated with AT rupture in men and
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women, respectively. The percentage of ruptures associated with sporting activities was
78.6%.
Gwynne-Jones et al (2011)27 conducted an epidemiological study in Dunedin, New
Zealand. They found an incidence of approximately 24 per 105 individuals over an 8.5
year period. Out of 363 AT rupture patients, 197 (54%) were males and 166 (46%) were
females. They also found an equal gender distribution up until the age of 50, but there
were significantly more males (73%, p=0.0007) in the age group 51-60 years. The mean
age of males was significantly higher than females [41.2 years (SD, 9.6) vs. 37.6 years
(SD, 9.3), p=0.0004]. The majority (78.5%) of AT ruptures occurred during sporting
events, with 31% of these attributed to netball.
More recently, Lantto et al (2014)28 examined the epidemiology of AT rupture over a 33
year period in Oulu, Finland from 1979 to 2011. There were 528 ruptures in 515 patients
(456 male, 59 female) with a mean age of 43 years for all patients (SD 13, range 19-90).
Sports-related injuries accounted for 70% of cases. The overall incidence increased from
2.1 (95% CI 0.3-7.7) per 105 person-years in 1979 to 21.5 (95% CI 14.6-30.6) per 105
person-years in 2011. For each 11-year period, the incidence of ruptures increased in all
age groups; in the first 11-year period (1979-1989) the highest incidence was in the 40-49
years old age group, but for the next two 11-year periods (1990-2000, 2001-2011) the
highest incidence was in the 30-39 year old age group.

2.2.2

Etiology

There are two main theories advocated for the cause of, or predisposition to, AT rupture
,

within the orthopaedic literature: the degenerative theory and the mechanical theory1 2.
Several other factors have also been associated with AT rupture but with little agreement
amongst researchers regarding definitive contributions17. These factors include poor
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tendon vascularity17,29, iatrogenic effects from drug therapies (corticosteroids,
fluoroquinolones, anabolic steroids)15,16,32, hyperthermia-associated rupture33, and
underlying genetic and autoimmune conditions34,35.

2.2.2.1

The Degenerative Theory

The degenerative theory suggests that chronic degeneration of the tendon leads to a
rupture without excessive loads being applied2. Arner et al (1959)36 were the first to
report degenerative changes in patients with AT rupture, however, the histologic
specimens were obtained more than two days post-rupture. Davidsson & Salo (1969)37
reported marked degeneration in the AT of two patients whom were operated on the day
of their injury, indicating that these changes had developed prior to rupture. Kannus &
Jozsa (1991)38 suggested that degenerative changes are common in the tendons of people
greater than 35 years of age, and that these changes can be associated with spontaneous
rupture. Additionally, failure of the extracellular matrix has been proposed to lead to
intratendinous degeneration. Jozsa et al (1989)39 observed fibronectin on the torn surfaces
of ruptured ATs. Fibronectin is normally located in basement membranes, and binds
more readily to denatured collagen than to normal collagen, indicating pre-existing
collagen denaturation40.

2.2.2.2

The Mechanical Theory

According to McMaster (1933)41, a healthy tendon would not rupture even when
subjected to a substantial strain. Barfred (1971)1,42, however, noted that McMaster’s
experiment involved applying straight traction to the tendon which would ultimately
distribute the strain equally throughout the muscle-tendon-bone complex rather than to
the tendon itself. Oblique loads or traction during maximal muscle contraction when the
tendon length is initially short yields the highest risk of rupture concentrated at the
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tendon42. These circumstances are likely common in many athletic movements requiring
a rapid push-off.
It has been demonstrated that participation in sports plays a significant role in the
development of AT problems43. Structural disturbances in lower leg mechanics from
overtraining, functional overpronation, and gastrocnemius-soleus insufficiency has been
proposed to lead to AT injury. Additionally, repeated microtrauma resulting from
eccentric loading of a fatigued muscle may also play an important role in tendon injury44.
Tendon rupture is ultimately a consequence of multiple micro-ruptures which lead to
failure of the tendon after reaching a critical point45.
Inglis and Sculco (1981)46 hypothesized that malfunction of the proprioceptive inhibitory
mechanism which prevents excessive or uncoordinated muscle contractions could cause
rupture of an otherwise normal tendon. They further proposed that this mechanism
explains why athletes who return to or begin training after a period of inactivity are at
greater risk for a rupture.

2.2.3

Mechanism of Injury

Arner & Lindholm47 were first to describe the three main categories of indirect trauma
resulting in AT rupture. The first category (53% of ruptures in their series) involved
pushing-off with the weight-bearing forefoot while extending the knee, as in a ‘sprintstart’ or jump initiation. The second category (17% of ruptures) involved a sudden,
unexpected dorsiflexion of the ankle. The third category (10% of ruptures) was violent
dorsiflexion of a plantarflexed foot, as would occur when falling from a height. In all of
these mechanisms, traumatic rupture occurs because the force exerted on the rapidly
loaded tendon exceeds the tendon’s tensile strength48.
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2.2.4

Clinical Presentation

Patients with acute AT rupture typically describe the sensation of being hit in the
posterior aspect of the lower leg at the time of rupture. Some patients report an audible
‘snap’. This is followed by pain, an inability to bear weight, an inability to plantar-flex
the ankle, weakness or stiffness in the calf muscle of the affected ankle. Physical
examination may reveal edema and bruising; a palpable gap may be felt along the tendon
at the site of the rupture, depending on the amount of swelling present. The calf-squeeze
test (Thompson test or Simmonds test) and the Knee-flexion (Matles) test are the most
sensitive (0.96, 0.88 respectively) and specific (0.93, 0.85 respectively) tests for
diagnosing AT rupture49.

2.2.4.1

Calf-Squeeze (Thompson or Simmonds) Test

The calf-squeeze test is performed with the patient prone on the examination table and
the ankles clear over the edge of the table. The examiner squeezes the bulk of the calf
muscle, deforming the soleus muscle and causing the overlying Achilles tendon to bow
away from the tibia, resulting in plantarflexion of the ankle if the tendon is intact50.
Limited or no movement of the ankle compared to the contralateral (i.e. uninjured) ankle
indicates a rupture51.

2.2.4.2

Knee Flexion (Matles) Test

Also lying prone on the examination table, patients are asked to actively flex their knees
to 90 degrees. During flexion, if the injured foot falls into neutral or dorsiflexion, an AT
rupture can be diagnosed52.
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2.2.4.3

Imaging

Although clinical examination is generally sufficient for a diagnosis of a full AT rupture,
some researchers have reported that more than 20% of full ruptures can be missed
clinically upon initial presentation 53–55. The ability to correctly distinguish a full versus a
partial rupture or tendinopathy has clinical implications that directly affect patient care,
as the treatment algorithm can be different for each diagnosis56. In a study evaluating the
ultrasonographic differentiation of full versus partial Achilles tendon ruptures, Hartgerink
et al (2001)56 reported the following results: sensitivity=100%; specificity=83%;
accuracy=92%; positive predictive value=88%; negative predictive value=100%.
Evidently, imaging can be a useful adjunct to clinical evaluation and diagnosis.

2.2.4.3.1

Ultrasonography

Ultrasonography (US) is a medical imaging technique that uses high-frequency sound
waves and their echoes to produce a two-dimensional image of anatomical structures57.
Superficial tendons, such as the AT, are well suited to evaluation by high-resolution realtime US58. US is a rapid, reliable, and cost-effective means of evaluating the integrity of
the AT56,59,60. US has been used increasingly in the investigation of the AT, from the
diagnosis of ruptures and tendinopathy to post-treatment followup56,61–63.
Ultrasonography of the AT with linear probes produces a dynamic and panaroamic image
of the tendon64. The AT is composed of longitudinally arranged collagen bundles, which
reflect the ultrasound beam. A normal AT appears as a hypoechogenic, ribbon-like image
that is contained within two hyperechogenic bands (Figure 2)65. Tendon fascicles appear
as alternate hypoechogenic and hyperechogenic bands that are separated when the tendon
is relaxed and more compact when the tendon is strained66. The number of fascicles that
are visible with US closely correlates with the frequency of the ultrasound probe used61.
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Figure 2 Ultrasonographic appearance of a normal Achilles tendon
Reproduced with permission of W.B./Saunders Co. in the format thesis/dissertation via Copyright
Clearance Centre (order detail ID: 68044510)

When the AT is ruptured, the site of rupture will appear as an “acoustic vacuum,” which
represents a gap in the tendon, with irregular edges on the ultrasonography image67,68
and possible hypoechoic fluid distension of the synovial sheath69 (Figure 3)56. Partial
tears appear as abnormal hypoechoic or anechoic clefts typically within an enlarged
tendon surrounded by anechoic or hypoechoic fluid69. In cases of diagnostic uncertainty,
dynamic evaluation of the tendon during dorsi- and plantar-flexion movements can aid in
detecting tendon discontinuity, which indicates full rupture70.
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Figure 3 Ultrasonographic appearance of a ruptured Achilles tendon
Reproduced with permission from Hartgerink, Fessell, Jacobson, et al (2001); Radiological Society of
North America; 220; 406-412

2.2.4.3.2

Magnetic Resonance Imaging

A magnetic resonance imaging (MRI) scan is a diagnostic imaging procedure whereby
powerful magnets and radio waves produce images of the internal structures of the body.
MRI is a powerful and versatile diagnostic tool that can provide definitive diagnoses for a
wide range of musculoskeletal pathology71. There are several factors that influence the
quality of the images obtained, including: lack of motion during the procedure; the signal
intensity and resolution of structures; and tissue contrast72. Different MRI sequences or
protocols are used when evaluating different structures of interest (i.e. tendons,
ligaments, bone, etc.) in order to optimize the intensity, resolution, and contrast of the
images72.
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2.3 Healing Following Achilles Tendon Rupture
Tissue regeneration and turnover in the Achilles tendon is an extremely slow process. It
has been demonstrated that the core of the AT are formed during skeletal growth and
maturity, with very little regeneration thereafter73. In contrast, the periphery of the tendon
is capable of altering its structure, composition, and mechanical properties in response to
mechanical forces through fibroblast-mediated biomechanical signaling. The
physiological and pathological changes associated with this process are not well
understood74,75.
The repair of injured tendons can generally be described in three overlapping phases: the
inflammatory phase; the proliferative or reparative phase; and the remodeling phase14,15
In the inflammatory phase, bleeding caused by the rupture leads to hematoma and
subsequent activation of platelets and neutrophils, which leads to the release of growth
factors, chemotactic factors, and vasoactive factors. These factors recruit tendon
fibroblasts to begin collagen (type III) synthesis and deposition. This phase of healing
generally lasts between 24 and 48 hours, but these processes can occur up to seven days
and overlap into the next phase of healing. Approximately three days after the injury, the
proliferative phase begins which is highlighted by increased angiogenesis and collagen
production. Water content and glycosaminoglycan concentration are high during this
time. After approximately six weeks, the remodeling phase begins and can last for several
years. This phase is characterized by decreased cellularity, decreased type III collagen
synthesis, and a gradual increase in type I collagen synthesis. The repaired tissue changes
to fibrous tissue, which again changes to scar-like tendon tissue after 10 weeks. During
the latter stages of remodeling, covalent bonding between collagen fibres increases which
results in higher stiffness and tensile strength in the repaired tissue14,15,74–77.

14

2.3.1

Clinical Assessment of Healing

The clinical assessment of AT healing uses many of the same criteria as the clinical
diagnosis of AT rupture (i.e. palpation of the tendon, Thompson’s test, Matles test).
Additionally, there are functional criteria that clinicians use to subjectively assess the
integrity and healing of the tendon such as the unilateral heel-rise test, active and passive
range of motion, and tendon elongation measures. During the heel-rise test, the patient is
asked to perform a heel-rise on their uninjured leg to establish a baseline, followed by a
heel-rise on their injured leg. A successful heel-rise is acknowledged if the heel can be
lifted at least 2 cm off of the ground with an extended knee. The heel-rise appears to
reflect the general level of subjective and objective healing in AT rupture patients78.
Tendon elongation can be assessed in the Matles test position, where if the injured foot
falls into neutral or dorsiflexion it is indicative of tendon elongation52. Passive range of
motion can also be assessed in this position.

2.3.2
2.3.2.1

Using Imaging to Assess Tendon Healing
Ultrasound

US is frequently used to diagnose tendon injuries, but is less commonly used to assess the
state of healing in these structures79. US studies that examined tendon structure after
rupture or tears of the Achilles tendon have qualitatively assessed several criteria,
including: the appearance of torn tendon ends; focal areas of echogenicity; peritendinous
reactions, such as edema or effusion; hyperemia via colour Doppler US; the presence of
calcifications; and the overall appearance of the tendon with respect to thickening or
thinning56,58,61,68,80,81. Several of these criteria are associated with other tendon
pathologies, such as tendinitis or tendinosis79,80,82. Additionally, these criteria have not
been consistently correlated with clinical or functional parameters81,83. The relative
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importance or contribution of each of these criteria to tendon healing after rupture is
therefore unknown.
Hollenberg et al (2000)61 described the gray-scale and colour Doppler sonographic
appearance of healed AT ruptures that have been treated non-operatively. A total of 11
patients were evaluated at baseline and at a mean of 22.4 (range 7-38) months postinjury, when the treating physician considered the patient clinically healed. Distortion of
the fibrillar architecture decreased markedly in all follow-up scans. In only 4 of 11 cases
were the tendon ends still visible at the torn rupture site (Figure 4)61. Gaps between the
torn tendon ends seen acutely in three patients were resolved upon tendon healing.
Hematomas were present in all initial scans, and were resolved in all but one follow-up
scan. The healed rupture sites were notable for mild residual distortion of the normal
fibrillar architecture, slight anterior bulging or irregularity of the healed tendon, and a
hypoechoic area at the site of prior rupture (Figure 5, Figure 6)61. The authors concluded
that the healed AT after rupture has a different appearance than a normal AT, but that
predictions of the appearance the healed tendon could not be made based on the
appearance of the initial ruptured tendon.
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Figure 4 Follow-up scan at 29 months demonstrating a healed tendon with resolution of
the hematoma (arrows). The overlapping healed ends remain visible
Reproduced with permission of Springer-Verlag in the format thesis/dissertation via Copyright Clearance
Center (order detail ID: 67331498)
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Figure 5 Follow-up scan at 15 months demonstrating a healed tendon with no
discernable gap. The hypoechoic band (white arrows) and the slight bulge along the
anterior margin of the tendon (black arrows) define the site of prior injury. There is mild
residual distortion of the normal fibrillar architecture
Reproduced with permission of Springer-Verlag in the format thesis/dissertation via Copyright Clearance
Center (order detail ID: 67331498)
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Figure 6 Follow-up scan at nine months demonstrating the healed tendon with a subtle
hypoechoic band indicating the site of previous rupture (white arrows). Note the irregular
contour along the anterior tendon (black arrows)
Reproduced with permission of Springer-Verlag in the format thesis/dissertation via Copyright Clearance
Center (order detail ID: 67331498)

Möller et al (2002)81 serially evaluated the AT at 6, 12, and 24 months after complete
rupture in patients that were randomized to operative and non-operative treatment. Edema
and tendon defects were a common finding at six months, but were detected with less
frequency after one year. Tendon thickening was noted in 100% of patients at 6 and 12
months, and a transition from a generalized thickness to a fusiform thickness was also
noted between these time points. A heterogeneous echogenicity pattern was present in
100% of patients at six months, and 97% of patients at one year. This is consistent with
the US findings of Rupp et al (1995)84, who found persistent heterogeneity from 2 to 19
years after surgical repair in 56 of 60 patients. The authors of this study concluded no
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significant difference in the number of positive imaging findings between operativelyand non-operatively treated patients. Furthermore, there was no correlation between the
US imaging outcomes and the clinical and functional outcomes of the patients. A
significant limitation of this study is that there was no baseline US images of the tendons
which prevents documentation of any changes in appearance between injury and six
months post-injury.

2.3.2.2

Magnetic Resonance Imaging

On MRI, a normal AT is generally low signal intensity on all pulse sequences. Some
normal ATs may have slightly increased signal intensity near its calcaneal insertion as a
result of non-tendinous fatty material interposed between the tendon fibers as it widens.
There is a solid vertical line of high signal intensity in the mid-substance of many normal
ATs, which likely represents the gastrocsoleus complex and should not be mistaken for
pathology85.
The first sign of tendon abnormality on MRI is often an increase in signal intensity,
which could represent a combination of fluid, hematoma, partial tears, or tendon lesions.
Complete rupture of the AT appears as a focal disruption with absence of the tendon
fibers for variable distances85 (Figure 7)86. Healing tendons are characterized by having
diffusely abnormal signal intensity and tendon thickening on most MRI sequences. From
an imaging standpoint, a tendon can be considered healed when the tendon is
satisfactorily aligned without a gap87.
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Figure 7 Full thickness tear of the Achilles tendon (T1-weighted sagital MRI). There is
discontinuity of the tendon with retraction of the proximal portion (red arrow). The distal
tendon is tendinopathic and appears thickened and of increased signal intensity (white
arrow).
Reproduced with permission of BIR in the format republish in a thesis/dissertation via Copyright Clearance
Center (order detail ID: 67464872)

Karjalainen et al (1997)88 examined MR images of 21 consecutively recruited patients
who underwent surgical repair after AT rupture. Images were obtained at 3, 6, 12, and 24
weeks post-surgery. Clinical and functional evaluation occurred at the same time points.
An intratendinous area of increased signal intensity (intermediate signal intensity, n=9;
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high signal intensity, n=10) was observed in 19 of 21 tendons at three months postrupture on proton density- and T2-weighted images. The three patients with the largest
tendon lesions at three months on MRI had clinically poor outcomes at three months.
Furthermore, patients with an abnormal gait pattern at three months (n=5) had
significantly larger intratendinous lesions than patients who could walk normally
(p=0.03). In all patients, the cross-sectional area of the healing AT showed the largest
increase between 6 weeks and 12 weeks post-surgery. Of the nine patients who had
intermediate signal intensity lesion at three months, only one patient had a lesion present
at six months. Of the ten patients who had areas of high signal intensity at six months,
nine still had areas of increased signal intensity but were all reduced in size. The authors
concluded that MRI provides a precise valuable tool to evaluate the post-surgical internal
structure of the AT. A potential limitation of this study is the use of the 0.1 T MRI
scanner, which would yield less contrast and detail in anatomic structures and areas of
increased signal intensity versus the conventional 1.5 T MRI scanners used in the present
study.
Fujikawa et al (2007)89 examined the MRI features of normal AT healing, specifically
with respect to the residual gap, in 30 patients who underwent percutaneous repair after
AT rupture. AT contour and contrast enhancement at the rupture site was also assessed.
Images were obtained approximately 4, 8, and 12 weeks post-surgery. A residual gap was
found in 100%, 80%, 0% of the tendons on T1-weighted images and 90%, 100%, and
100% of the T2-weighted images at 4, 8, and 12 weeks, respectively. At eight weeks
post-surgery, palpation of the tendon by the clinician did not confirm the presence of a
gap despite the tendon gap appearing on MR images. The authors hypothesized that the
original gap at the rupture site may have been filled with granulation tissue at eight
weeks, but mature fibrous tissue is likely absent. This suggests that palpation of the AT
may not be an accurate reference standard for assessing tendon fusion. Intratendinous
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enhancement (i.e. abnormal signal intensity) was present in 100%, 73%, and 7% of the
tendons at 4, 8, and 12 weeks post-surgery. The authors concluded that the tendon gap
visible on MR images can be expected to disappear approximately 12 weeks postsurgery, and that the time-course of the MRI features of the AT after percutaneous repair
can be considered to reflect normal healing.

2.3.2.3

Ultrasound Versus MRI in Assessing Healing of Tendon
Injuries

Both MRI and US are well-suited to tendon imaging and evaluation, but MRI has been
considered the gold standard because of its ability to provide a broader anatomic
overview and excellent soft tissue contrast90. However, US is a more rapidly performed
examination, has greater spatial resolution than MRI, and allows for the dynamic
evaluation of the tendon. Furthermore, the advent of US extended-field-of-view imaging
allows an image of the entire length of the tendon to be obtained, similar to MRI’s ability
to display a large anatomic region. It has been proposed90 that US should best be
considered a focused examination that concentrates on a distinct area of clinical suspicion
of pathology, whereas MRI can provide a global assessment of a region of concern.
Several studies that have used both US and MRI to assess various tendon abnormalities
have found comparably high levels of accuracy with both modalities56,59,91–94. A recent
meta-analysis95 of 65 studies comparing MRI, US, and MR arthrogram of rotator cuff
tendon tears found that MRI and US were grossly comparable in both sensitivity (85.5%
versus 85.1%, respectively; 95% CI=83.7% to 87.3% versus 83.5% to 86.7%,
respectively) and specificity (90.4% versus 92%, respectively; 95% CI=89.2% to 91.6%
versus 90.8% to 93.2%, respectively). These results, combined with the lower cost and
testing duration, suggest that US may be the most cost-effective method of screening for
rotator cuff tendon tears. With respect to the longitudinal assessment of tendon healing,
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however, Connell et al (2004)94 found that MRI was more sensitive than US to follow-up
imaging of healing hamstring tendons. To our knowledge, there have been no studies that
have longitudinally evaluated the healing AT using both US and MRI.

2.4

Treatment of Achilles Tendon Rupture

AT rupture can be managed by both operative and non-operative strategies, although
there is controversy as to which is the optimal treatment. The reason for this controversy
is that each treatment has unique advantages and disadvantages. Specifically, operative
treatment has been associated with a lower risk for re-rupture but a higher risk for
complications (deep infection, deep vein thrombosis, extreme tendon lengthening, scar
adhesion, sensibility disturbance), whereas non-operative treatment has previously been
associated with a higher risk for re-rupture but lower risk for complications3,96,97.
However, there is recent evidence to suggest that the differing rehabilitation protocols
between operative and non-operative management can significantly affect re-rupture rate.
When accelerated functional rehabilitation is employed, similar re-rupture rates are
evident between operative and non-operative treatment5,98–103. There is little consensus
regarding differences in functional recovery between operative and non-operative
treatment, primarily due to inconsistencies in how this is assessed96.

2.4.1

Operative Treatment

Operative treatment options for AT rupture include open, minimally invasive, and
percutaneous repair104. There are several open surgical techniques, but there is no
evidence that adequately demonstrates the superiority of one method over another. Open
surgery involves passing heavy, non-absorbable sutures through each stump of the
tendon105. Evidence suggests that the strength of the repair is directly proportional to the
number of strands that cross the repair site106. Percutaneous repair involves using stab
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wounds to pass suture through the tendon. This technique minimizes the risk of
complications associated with open surgical repair but increases the risk for sural nerve
injury107,108.
A recent systematic review conducted by Del Buono et al (2014) compared minimally
invasive (including percutaneous repair) and open surgical techniques for treatment of
AT rupture. They found that minimally invasive surgery yields a lower rate of
complications (re-rupture, deep infections, deep vein thrombosis, and scar adhesion), than
open surgery, with comparable functional outcomes (range-of-motion, strength, return to
work time), clinical outcomes (pain, calf-circumference) and patient-reported outcomes
(AOFAS scale). It was also noted that minimally invasive surgery is less expensive, less
time-demanding, and more cosmetically appealing than open repair but future research
should address the minimization of iatrogenic complications to the sural nerve during
percutaneous repair.

2.4.2

Non-Operative Treatment

Surgical and post-surgical complications have been the primary reason behind the
continued focus on non-operative management of AT ruptures. Traditionally, nonoperative treatment consisted of immobilized casting of the lower extremity for eight
weeks, followed by a standardized rehabilitation protocol. Reports of decreased range of
motion, muscle atrophy, and loss of proprioception associated with immobilization109
have recently challenged this approach. Instead, early dynamic mobilization and weightbearing with removable below-knee orthoses has become increasingly advocated, as it
has been suggested that this can reduce the high risk for re-rupture associated with nonoperative treatment5,98,110.
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2.4.3

Operative vs. Non-Operative Treatment: A Review of the
Literature

A meta-analysis conducted by Bhandari et al (2002)111 reviewed articles comparing
operative versus non-operative treatment of AT ruptures in the Medline, Grateful Med,
and Cochrane databases from 1969 to 2001. The primary outcome of interest was rerupture rate, and secondary outcomes included deep infection rates, return to normal
function, and spontaneous complaints. Three investigators independently reviewed
abstracts and graded study quality. Of 273 citations initially identified, six met all
eligibility criteria (n=448 patients). Pooled analysis revealed that surgical repair
significantly reduced the risk of re-rupture when compared with non-operative treatment
(3.1% versus 13%, respectively; RR=0.32; 95% CI=0.14 to 0.71; p=0.005). Five studies
provided information on infection rates (n=421 patients) and it was demonstrated that
infections only occurred in surgically treated patients (4.7%; range 4% to >20%). The
relative risk (RR) of infection with surgical repair was 4.6 times greater than the cast
treatment (95% CI 1.2 to 17.8; p=0.03). There was no significant difference in return to
normal function and spontaneous complaints. The authors could not provide a strong
recommendation for surgery based on these results.
Khan et al (2005)97 meta-analyzed all randomized, controlled trials (RCTs) comparing
operative and non-operative methods for the treatment of AT rupture. The databases
searched included in their search were Embase, CINAHL, and Medline. The outcomes of
interest were re-rupture and treatment complications as these were the only consistently
reported outcomes that were conducive to meta-analysis. Four reviewers independently
assessed all trials and assigned study-strength scores based on methodological rigor. Of
the 36 articles identified with their search strategy, 24 were excluded due to retrospective
study design, inadequate randomization, and insufficient information. The pooled rerupture rate for operative treatment versus non-operative treatment was 3.5% (6/173) and
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12.6% (23/183), respectively (RR=0.27; 95% CI=0.11 to 0.64). With respect to treatment
complications (infection, scar adhesion, disturbed skin sensibility) operative treatment
was associated with a higher risk compared to non-operative treatment (34.1% versus
2.7%, respectively; RR=10.60; 95% CI=4.82 to 23.28). The authors noted that future
prospective, randomized studies should include larger samples, full reporting of
outcomes, and blinded assessors in order for more accurate meta-analysis.
More recently, Jiang et al (2012)96 conducted a meta-analysis comparing operative versus
non-operative management of AT rupture. Two authors searched six electronic databases
(Medline, Embase, Clinical Ovid, BIOSIS, and Cochrane registry of controlled trials) for
RCTs between 1980 and 2011. Ultimately, ten trials were recruited for meta-analysis
(n=894 patients). The modified Jadad scale was used to assess methodological quality,
with eight studies being deemed good or excellent. The primary outcomes of interest
were incidences of re-rupture and complications other than re-rupture. Secondary
outcomes included the number of patients who returned to pre-injury sports, mean time
for sick leave, and results for subgroup analysis (scar adhesion, superficial infection, deep
vein thrombosis, sensibility disturbance). The results of the meta-analysis revealed that
the operative group had significantly lower re-rupture rate compared to the non-operative
group (4.31% versus 9.71%, respectively; RR=0.44; 95% CI=0.26 to 0.74; p=0.002). The
operative group demonstrated significantly higher complication rates than the nonoperative group (26.6% versus 7.19%, respectively; RR=4.07; 95% CI=1.56-10.67;
p=0.004). The mean time for sick leave was shorter following operative treatment than
non-operative treatment (MD=-23.75; 95% CI=-41.6 to -5.89; p=0.009). There was no
significant difference between the two methods in the number of patients who returned to
pre-injury sports. Significant differences were found in favour of the non-operative group
with respect to scar adhesion (RR=11.76; 95% CI=4.64 to 29.80; p<0.00001), superficial
infection (RR=4.43; 95% CI=0.97 to 20.23; p=0.05), and sensibility disturbance
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(RR=7.53; 95% CI=2.55 to 22.18; p=0.0003). There were no significant differences
regarding deep infection or extreme Achilles tendon lengthening. Functional assessment
could not be assessed in this meta-analysis due to a lack of standardized assessment
systems. A significant limitation of this meta-analysis is that the authors did not
separately analyze studies that used immobilization versus those that used early
mobilization, which is an important distinction since early mobilization has been shown
to equalize outcomes4,5
Soroceanu et al (2012)5 conducted a meta-analysis of RCTs comparing operative versus
non-operative treatment of AT rupture. Two independent reviewers screened 615
abstracts within the most commonly used medical databases (Cochrane, Medline, Web of
Science, and Embase) and was the first meta-analysis to include foreign language papers.
Ten studies were used for meta-analysis (n=826 patients). The main outcomes of interest
were re-rupture rate and complications other than re-rupture (infection, skin and tendon
necrosis, fistulas, scar adhesion, sural nerve damage, decreased ankle motion, deep vein
thrombosis, and pulmonary embolus). Meta-analysis revealed that if functional
rehabilitation with early range-of-motion was employed, there was no significant
difference in re-rupture rate between operative and non-operative management
(RD=1.7%; p=0.45). However, if the non-operative treatment protocol involved
prolonged immobilization the absolute risk reduction (ARR) in the re-rupture risk was
8.8% in favour of the surgical intervention (p=0.001). With respect to other
complications, meta-analysis revealed that the risk difference (RD) was 15.8% in favour
of non-surgical treatment (p=0.016). The authors of this trial suggested that non-surgical
management is equivalent to surgical management with regard to re-rupture rate when
functional rehabilitation with early range-of-motion is employed.
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2.5

Rehabilitation: Immobilization versus Early
Mobilization

Over the past decade, rehabilitation has shifted from immobilizing management towards
early mobilization112. The concept of mobilization can be further divided into: controlled
early motion, controlled early weight-bearing, or a combination of both. Controlled early
motion can be achieved with the use of a dynamic brace which permits movement of the
ankle, or using a removable brace and instructing patients to periodically remove the
brace and perform ankle exercises75. There are varying descriptions of controlled early
weight-bearing protocols, however, they generally involve functional bracing of the ankle
in an equinus position and weight-bearing immediately post-rupture.
There are several physiological and biomechanical factors that explain the benefits of
early mobilization instead of immobilization for rehabilitation protocols113. Compared to
immobilization, early mobilization will: increase blood and lymphatic flow to aid in
healing114–117; produce tension to stimulate tissue repair for faster healing117–119; produce
tension to improve tissue alignment during healing120–122; limit connective tissue
fibrosis119–121,123,124; preserve coordination caused by neuromuscular activation from
exercise and movement125,126; preserve ROM to avoid or minimize joint fibrosis120,121,127;
maintain proprioceptive functions123,124; produce quicker recovery and return to
activity114,121,123,127. However, in situations where there are severe open wounds or
fractures associated with muscle, tendon, or ligament injuries then immobilization may
be necessary113.

2.5.1

Controlled Early Motion

Cetti et al (1994)99 prospectively randomized 60 patients who underwent operative repair
of AT rupture to be placed in a new mobile cast (n=30) or a rigid below-knee
immobilizing cast (n=30). The mobile cast was constructed such that to allow motion and
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weight-bearing as-tolerated during the casting period. All patients had their casts
removed at six weeks post-rupture. All patients in the rigid cast group reported painful
edema of the injured leg daily during the casting period; there were no such reports in the
mobile cast group. Twenty-three patients (77%) thought that the mobile cast was
excellent, and six patients (20%) thought that the rigid cast was excellent (p<0.00005).
Patients in the rigid cast group had significantly greater calf muscle atrophy upon
removal of the cast compared to the mobile cast group (28.7 mm; range = 10-45 mm
versus 18 mm; range 8-30 mm, respectively; p=0.0019). Upon removal of the cast at six
weeks patients in the mobile cast group had significantly greater active range-of-motion
in the ankle compared to the rigid cast group (54.3°; range 30° dorsiflexion to 70° plantar
flexion versus 29.5°; range 5° to 60° plantar flexion, respectively; p<0.00001). Ankle
mobility remained significantly greater in the mobile cast group at six months and one
year (p<0.01). With respect to plantar flexion calf strength, the mobile cast group was
significantly stronger at three months, six months, and one year post rupture (p<0.01).
There was no statistically significant difference in re-rupture rate between the mobile cast
group and rigid cast group. The results of this study suggest early mobilization can lead
to favorable outcomes with respect to pain, range of motion, and strength compared to
immobilization.
Mortensen et al (1999)100 conducted a randomized control trial comparing early restricted
motion of the ankle (n=36) versus conventional cast immobilization (n=35) in postoperative AT rupture patients. Early restricted motion was accomplished by bracing the
patients in an equinus position (30 degrees plantar flexion) with an elastic band that
permits active dorsiflexion to neutral positioning. The immobilization group was casted
with their ankle in the equinus position. Both groups were in their respective braces for
six weeks post-surgery. The early motion group had significantly greater range of motion
than the immobilizing group upon removal of the brace/cast (p<0.001) and at 12 weeks
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(p<0.05) post-surgery. There were no differences between groups at the final clinical
assessment, which ranged from 12 to 24 months post-surgery. There were no significant
differences between groups regarding atrophy of calf muscles. The early motion group
had significantly better outcomes with respect to subjective result of rehabilitation
(p<0.05), scar-adhesion complications (p<0.01), earlier time to resume sports (p<0.001),
and earlier time to return to pre-injury sport status (p<0.001). There was one re-rupture in
the early motion group, and two in the immobilizing group. The authors concluded that
early motion appears to shorten the rehabilitation period while posing no additional
adverse risks, suggesting that larger studies are warranted to confirm these findings.
A randomized control trial by Kangas et al (2003)101 compared early functional treatment
(n=25) versus cast immobilization (n=25) in post-operative AT rupture rehabilitation.
Early functional treatment involved movement of the ankle from active plantar flexion
and active dorsiflexion to neutral while in a brace for six weeks post-surgery, whereas
immobilized patients’ ankles were fixed at neutral for six weeks. The isokinetic calf
muscle strength scores were excellent in 56%, good in 32%, fair in 8%, and poor in 4%
of the patients in the early functional treatment group and excellent in 29%, good in 50%,
and fair in 21% of the immobilized patients. There were no significant differences with
respect to pain, stiffness, subjective calf muscle weakness, or footwear restrictions
between groups. There was one re-rupture in the early functional treatment group and two
in the immobilization group. The authors advocated the use of early functional treatment
due to the potential for slightly better strength outcomes while obtaining similar results in
all other functional and subjective outcomes.

2.5.2

Controlled Early Weight-Bearing

Suchak et al (2008)102 prospectively randomized post-operative AT rupture patients to a
rehabilitation protocol that included early weight bearing (n=55) or non-weight bearing
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(n=55). Early weight bearing commenced at two weeks post-surgery, whereas the nonweight bearing group was immobilized and non-weight bearing for six weeks postsurgery. At six weeks, the early weight bearing group had significantly higher scores on
the RAND-36 domains of physical functioning, social functioning, role-emotional, and
vitality scores (p<0.05). Additionally, patients in the early weight bearing group reported
fewer limitations of daily activities at six weeks (p<0.001). There were no significant
differences between groups at six months. The authors concluded that early weight
bearing improves the patients’ quality of life in the early post-operative period with no
detrimental effect on long-term recovery.

2.5.3

Controlled Early Motion and Weight-Bearing

Saleh et al (1992)128 conducted a RCT to compare the effects of early motion and weight
bearing (i.e. early mobilization) versus cast immobilization in the non-operative
management of patients with AT rupture. Patients randomized to the early mobilization
group were placed in a cast for three weeks followed by controlled movement in a
Sheffield splint for three to eight weeks. Those in the immobilization group wore a fullleg cast with for four weeks followed by four weeks in a below-knee cast, with weight
bearing permitted during the final two weeks. Patients in the early mobilization group had
significantly greater dorsiflexion at 3, 6, and 12 months post-rupture (p<0.001). Patients
in this group also regained mobility (i.e. ability to comfortable weight bear) significantly
more quickly than patients in the immobilization group (mean=6 versus 11 weeks,
respectively; p<0.001). There was one re-rupture in each group. No differences between
groups were found regarding plantar flexion range-of-motion or strength at any interval.
These results suggest that early mobilization can lead to quicker recovery of dorsiflexion
and quicker return to normal activities than immobilization in a plaster cast.
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Costa et al (2006)129 conducted two RCTs comparing immediate weight bearing
mobilization versus cast immobilization in patients with AT rupture. In the first RCT, 48
patients consented to operative management of their injury (n=23 randomized to
immediate mobilization group, n=25 to control group). In the second RCT, 48 patients
consented to non-operative management of their injury (n=22 randomized to immediate
mobilization group, n=26 randomized to control group). Patients in the operative trial
began their respective rehabilitation assignments on the first post-operative day. Those in
the immediate weight bearing mobilization group were placed in a carbon-fiber orthosis
with three 1.5 cm heel-wedges, and those in the immobilization group were placed in a
plaster cast. Patients were reviewed every two weeks for an eight week period, where the
number of wedges or equinus position of the plaster was reduced at each visit. The cast or
orthoses were discontinued at eight weeks. A significant difference was found in favor of
the immediate mobilization group versus the control group for the time to return to
walking (median=12.5 weeks versus 18 weeks, respectively; 95% CI=10 to 18 versus 18
to 22; p=0.027) and stair climbing (median=13 weeks versus 22 weeks, respectively;
95% CI= 10 to 18 weeks versus 18 to 22 weeks, respectively; p<0.023). There were no
significant differences regarding time to return to work or sport, or quality-of-life
assessments (EQoL and E5D). There were two re-ruptures in the treatment group due to
breaching the rehabilitation protocol. The authors provided further evidence of improved
functional outcomes for patients immediately mobilized following operative repair of AT
rupture.
In the second trial129 the same protocol was employed, with the exception of the orthosis
or cast being removed at twelve weeks instead of eight and the removal of wedges or
plaster at two-weekly intervals after the six week mark. There were no significant
differences between any of the outcome measures in the second trial. There was one rerupture in the treatment group and one re-rupture in the control group. There were no
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significant differences in any of the functional or clinical outcomes for the non-operative
trial. The authors suggested, however, that the practical advantages associated with
immediate mobilization do not appear to predispose patients to a higher re-rupture rate.
They ultimately recommend immediate weight bearing mobilization for all AT rupture
patients. It should be noted that, overall, these trials are subject to selection bias as older
individuals were recommended non-operative treatment whereas younger and more
active individuals were recommended operative treatment, ultimately preventing any
between-group comparisons.
More recently, Barfod et al (2014)103 completed a RCT comparing early motion and
weight bearing (n=30) to early motion without early weight bearing (n=30) in the nonoperative treatment of patients with AT rupture. Both groups remained in a foot orthosis
for eight weeks, with controlled early motion commencing at two weeks post-rupture.
The only difference was that the intervention group could begin weight bearing
immediately. The results yielded no significant differences between groups with respect
to the Achilles Tendon Total Rupture Score (ATRS), heel-rise work, heel-rise height,
time to return to work, or time to return to sport. A significant difference was found in
favor of the early weight-bearing group for the quality of life during the eight weeks of
treatment (p=0.009). There were three re-ruptures in the treatment group and two reruptures in the control group. The authors concluded that immediate weight bearing
appears to be a safe recommendation that can improve quality of life during the nonoperative treatment period of AT rupture patients.

2.6
A Novel Non-Operative Option: Platelet-rich
Plasma
Platelet-rich plasma (PRP) is a generic term referring to products that contain autologous
blood-derived platelets concentrated in a small volume of plasma. Specific PRP products
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differ with respect to the commercial preparation system used, the absolute concentration
of platelets, the presence or absence of platelet activators, the presence or absence of
leukocytes, and the delivery technique to the tissue site7. PRP has been used in several
fields of medicine including cardiovascular surgery, plastic surgery, dental surgery, and
more recently in the treatment of orthopedic injuries130. Platelets are recognized as the
primary source of the growth factors and proteins that are responsible for initiating and
regulating tissue healing through the recruitment, proliferation, and differentiation of
cells at the site of injury131. The theoretical concept that concentrating platelets at the site
of tissue damage could optimize healing mechanisms provides the rationale for the
continued research of PRP in the treatment of orthopedic injuries.

2.6.1

Platelet Biology

Platelets, also called “thrombocytes,” are cytoplasmic fragments of megakaryocytes and
are formed in the bone marrow. They are round or slightly oval in shape, measuring
approximately 2 µm in diameter. Platelets are anucleate but contain organelles and
cellular structures such as mitochondria, microtubules, and granules (α, δ, λ)131. The αgranules are most abundant132 and are the primary source of the growth factors and
bioactive proteins that are involved in haemostasis and tissue healing133.
Platelets circulating in the blood stream are inactive; they become activated by von
Willebrand factor, collagen (exposed endothelium), or thrombin binding to respective
platelet receptors which ultimately initiates a haemostatic intracellular signaling
cascade134. Subsequently, histopromotive factors released by the platelets facilitate tissue
healing via cellular chemotaxis, proliferation and differentiation of cells, removal of
tissue debris, angiogenesis, and the formation of the extracellular matrix135,136. More
detail regarding this process is provided below.
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2.6.1.1

Proteins and Growth Factors in PRP and their Roles

The α-granules of the platelet contain and secrete more than 60 bioactive proteins and
growth factors that initiate and/or regulate tissue healing133. Table 1133 outlines these
proteins and growth factors in their functional categories and their respective biological
role. It should be noted that, although proteins are grouped according to function, some
may have multiple potential roles.
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Table 1 Platelet α-granule contents and their functional categories. Secreted proteins with
reported pro-angiogenic properties are underlined while those with anti-angiogenic
potential are also identified (*).
Reproduced with permission from Anitua et al. Autologous platelets as a source of proteins for healing and
tissue regeneration. Thrombosis & Haemostasis 2004; 91. 4-15
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2.6.1.2

Mechanism of Effect on Tissue

Upon platelet activation, the α-granules fuse to the platelet cell membrane where the
proteins and growth factors are completed to a bioactive state by the addition of histones
and carbohydrate side chains. The secreted growth factors immediately bind to the
external surface of cell membranes of cells of the damaged tissue via transmembrane
receptors, ultimately initiating an intracellular signaling cascade which results in the
expression of genes responsible for cellular proliferation, matrix formation, osteoid
production, collagen synthesis, etc. After the initial burst of PRP-related growth factors,
the platelets synthesize and secrete additional growth factors for the remaining seven
days of their life span. Once the platelet is exhausted and dies off, the macrophage, which
has arrived in the region via the vascular in-growth (i.e. angiogenesis) stimulated by the
platelets, assumes the function of wound healing regulation by secreting some of the
same growth factors as well as others137.

2.6.2

Preparation of PRP

A sample of PRP can be prepared in various pre-treatment settings, including a
laboratory, operating room, or a clinic. Once a patient’s blood has been obtained, the
autologous PRP sample can be prepared in minutes. There are three methods of
preparation to obtain a sample of PRP: gravitational platelet sequestration (GPS),
standard cell separators, and autologous selective filtration technology
(plateletpheresis)131.
The first method, the GPS is a table-top centrifuge system that separates anti-coagulated
blood into three distinct layers of red blood cells, white blood cells, and plasma from
bottom to top, respectively. The PRP yield is approximately 10% of the volume of blood
drawn. It is important to note that not all centrifugal devices are adequate for the purposes
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of preparing PRP, as the centrifugation force may be a critical step in yielding
undamaged platelets in the PRP sample131.
The second method, standard cell separators generally use a continuous-flow centrifuge
bowl or a continuous-flow disk separation technique and both a hard (fast) and a soft
(slow) spin, yielding platelet concentrations from 2 to 4 times baseline138. In this method,
a full unit of blood is required from the patient. Most of the red blood cells and plateletpoor plasma can be returned to the patient to maintain circulating volume139.
The final method, selective filtration technology or plateletpheresis depends on a singleuse disposable proprietary filter designed to concentrate platelets from whole blood. The
platelets are captured on the filter and are then harvested to provide a platelet-rich
concentrate (PRC) without the need for centrifugation. This method yields a similar
platelet concentration compared to the commercial centrifugation method140.

2.6.2.1

Classification of PRP

Each preparation method will yield a different PRP product with respect to platelet
concentration, the presence (buffy-coat) or absence of leukocytes, and the need of a
platelet activator (Table 2)7. It is also important to note that an individuals’ platelet count
can vary considerably on different days, which could also impact the concentration of
platelets in a sample of PRP141. Furthermore, this information is rarely documented in
PRP trials, which ultimately limits the ability to make comparisons and meta-analyze
data across these trials. DeLong et al (2012)7 have proposed a classification system that
enables efficient identification of the contents in a PRP sample (Figure 8). Identifying
and classifying the contents of PRP samples is a major step towards potentially
discovering an optimum dosage or preparation method of PRP7.
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Table 2 Plasma-Based and Buffy Coat-Based PRP Systems
Reprinted from The Journal of Arthroscopy & Related Surgery, 28 (7), Delong, Russel, & Mazzocca,
Platelet rich plasma: the PAW classification system, 998-1009, 2012, with permission from Elsevier

40

Figure 8 PRP "PAW" Classification System
Reprinted from The Journal of Arthroscopy & Related Surgery, 28 (7), Delong, Russel, & Mazzocca,
Platelet rich plasma: the PAW classification system, 998-1009, 2012, with permission from Elsevier

2.6.3

Delivery of PRP

Once a PRP sample is prepared, it is stable in the anticoagulated state for eight hours142.
In some instances anticoagulants are used to maintain platelet viability. Anticoagulant
citrate dextrose-A (ACD-A) and citrate phosphate dextrose (CPD) are the most
commonly used, with the latter being less effective of the two143. Upon delivery or
application of PRP, the platelets must be activated to release the contents of their αgranules, which can be accomplished exogenously or endogenously. Exogenous
activation via external clotting factors results in rapid coagulation of platelets and clot
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formation and for this reason are generally applied manually to the tissues, rather than
administered by injection7. Common exogenous platelet activators include thrombin,
calcium chloride, and calcium chloride plus thrombin. Endogenous activation occurs via
the platelets binding to exposed tissue collagen and, to a lesser extent, needle-induced
bleeding from an injection144.

2.6.4

PRP in the Treatment of Orthopedic Injuries

A meta-analysis was conducted by Sheth et al (2012)130 to determine the efficacy of
autologous blood concentrates in the treatment of orthopaedic bone and soft-tissue
injuries. They screened 895 potential studies in Medline and Embase databases and
identified 23 randomized controlled trials and ten prospective cohort studies that
compared PRP or autologous blood concentrates with a control therapy in patients with
an orthopaedic injury. Of the 33 studies, 10 examined ligamentous injuries, 14 examined
bone injuries, and 9 examined tendinous injuries. A total of 27 different functional
outcome measures were used, 11 of which served as the primary outcome of the study.
Of the 23 RCTs, six showed that PRP provided a significant functional benefit, 15
demonstrated no difference, one showed that the control provided significant functional
benefit, and one did not evaluate functional outcomes. Of the 10 prospective studies, 3
showed PRP provided a significant functional benefit, 6 demonstrated no difference, and
1 showed that the control provided significant functional benefit. There were no
commonalities amongst the studies that found a benefit to PRP with respect to: the type
of procedure or pathology; the PRP manufacturer/preparation method; the use of an
anticoagulant; the activation method; the number of PRP treatment applications; or the
volume of PRP used per treatment. The authors concluded that their analysis was limited
by marked variability among the studies.. Ultimately, these results suggested that there
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was uncertainty regarding the evidence supporting the use of PRP in the treatment of
orthopaedic injuries.
A similar conclusion was reached by Willits et al (2013)6 who reviewed the literature
regarding the use of PRP in the treatment of orthopaedic injuries. Many of the studies
included in the aforementioned meta-analysis130 were part of this review. Studies were
selected for review based on the highest levels of evidence. A total of 17 studies were
selected for review: 13 RCTs, two retrospective cohort studies, one prospective cohort
study, and one pilot study. Of the 17 studies, 10 examined PRP in the tendon healing, 2
examined PRP in bone healing, 2 examined PRP in muscle healing, and 3 examined PRP
in the treatment of intra-articular pathologies. A systematic review and subsequent metaanalysis on the clinical efficacy of PRP in arthroscopic rotator cuff repair was also
reviewed. The conclusions of this review suggest no clear indications for the use of PRP
in the treatment of musculoskeletal injuries. This is largely due to a lack of homogenous,
high level studies, which precludes attempts to compare results across PRP studies.

2.6.5
2.6.5.1

PRP in the Treatment of Achilles Tendon Ruptures: A
Review of the Literature
Animal Trials

In an animal study, Aspenberg & Virchenko (2004)9 examined effect of platelet
concentrate (PC) injections on AT repair in an established rat model. Sprague-Dawley
rats (n=263) had their AT surgically transected transversely 3 mm proximal to the
calcaneal insertion and a 3 mm long segment was also removed to enlarge the defect. The
rats were then randomized to the treatment or control (saline) group by taking coloured
marbles out of a hat, randomizing groups of ten rats at a time. Whole blood was collected
from three donor rats to prepare the PC sample for injection. The injections took place six
hours after the transection. Initially, 20 rats were randomized to receive the PC injection
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or control injection. At eight days, the rats were killed and their AT was removed to
undergo mechanical evaluation using a material-testing machine that fixed each end of
the tendon between two metal clamps and pulled at a speed of 1mm/s until failure. Peak
force, stiffness, and energy uptake was recorded for each mechanical evaluation. After a
significant improvement was found for this initial test, a repeat experiment was
performed which did not reach statistical significance. The authors then conducted three
additional experiments using the same parameters. Four more experiments were
conducted with different times allotted for healing (11, 14, 21, and 28 days). Mechanical
evaluation of the tendons occurred for each of these additional experiments, and
histological evaluation of the tendons occurred in the 11 day- and 21 day healing
experiments. The eight-day results indicated a significant increase in force at failure
(mean=27%; 95% CI=10-44%; p=0.001) and stiffness (mean=35%; 95% CI=14-56%;
p<0.001) in favor of the PC group. No significant differences were observed regarding
maximum stress or energy uptake between groups. The reported mechanical results for
the remaining healing times are as follows: the force at failure was increased at for all
times (p<0.001) with the largest difference occurring at 21 days (mean=36%; 95% CI=567%); the transverse area was increased by PC treatment at 8 and 11 days, but after 14
days the areas were similar in both groups; the maximum stress was increased in all PC
treatment groups (p=0.004); The stiffness in all groups increased with healing time
(p<0.001) and with PC (p<0.001), with the largest effect of PC at 11 days (mean=41%;
95% CI=12-70%); the energy uptake in all groups was increased with time (p<0.001) and
with PC treatment (p=0.02), with the largest effect at 21 days (mean=18%; 95% CI=12%-48%). The histological findings indicated that PC treatment had no detectable effect
at 11 days (p=0.40), but at 21 days the tendon calluses in the PC group were more mature
(p=0.02). Although promising, the results of this study should be interpreted cautiously as
the methodology of the study should be questioned. The authors did not clearly state a
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priori that it was their intention to conduct five sets of identical trials, as it seems that
they conducted the additional trials due to the second trial not reaching statistical
significance. Furthermore, the effect of PC in these trials was highly variable which the
authors attribute to premature platelet activation in some batches of PC samples. The
authors ultimately concluded that a single PC injection can improve tendon repair in rats
and that these effects can be seen up to four weeks post-injection.
Stemming from the results of Aspenberg & Virchenko (2004)9, Virchenko & Aspenberg
(2006)10 evaluated the interplay between platelet-concentrate (PC) injections and
mechanical loading in a rat model in an attempt to explain the lasting effects of a single
PC injection on AT repair. Tendons were either unloaded with Botulinum toxin A (Botox)
or mechanically stimulated in activity cages. Sprague Dawley rats (n=130) were used in a
series of separate trials with ten rats in each respective group. All experiments included
tendon transection with spontaneous healing and were evaluated mechanically. All
experiments were evaluated after 14 days except the final experiment which was
evaluated at 5 days. In the first experiment, 20 rats received Botox injections and
underwent tendon transection seven days later, at which time paralysis (i.e. unloading)
appeared complete. Six hours after tendon transection, the rats were randomized to
receive an injection of PC (n=10) or a buffer control injection (n=10). This trial
demonstrated that with unloading by Botox, there were no stimulatory effects of PC
which suggests that mechanical loading is a prerequisite for stimulation of repair by
platelets. In the next experiment, 20 rats were randomized to activity cages or normal (i.e.
non-activity) cages. After an acclimatization period to their cage, the rats underwent
tendon transection and returned to their cages. Upon mechanical evaluation 14 days later,
the tendons from activity cages had increased force, energy uptake, and transverse area.
This experiment was then repeated with the addition of platelet gel, yielding 4 separate
groups: activity cage rates with platelet gel; activity cage rats with no platelet gel; normal
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cage rats with platelet gel; and normal cage rats with no platelet gel. These results
showed that platelets increased stiffness, reduced area, and increased stress at mechanical
failure of the tendon. There was no evidence to suggest that cage activity influenced the
tendon’s response to platelets. The authors then combined the results of the activity cage
experiments (excluding platelet-treated groups from the aforementioned trial) and found
that activity increased force (mean increase=12%; 95% CI=0.8-23%; p=0.04), energy
uptake (mean increase=18%; 95% CI=2-34%; p=0.04), and tendon area (mean
increase=24%; 95% CI=4.6-43%; p=0.02). In the final experiment, 40 rats received
Botox injections, followed by randomized to platelet or control treatment after tendon
transection and were evaluated after five days. These results showed that platelet
treatment increased force (mean increase=37%; 95% CI=11-63%; p=0.01), stiffness
(mean increase=52%; 95% CI=15-87%; p=0.01), and area (mean increase=64%; 95%
CI=-25-154%; p=0.009). In summary, these results suggest that activity (i.e. mechanical
loading) increases size (and thereby force and energy) of the tendon and platelets
improve material properties early in the healing process. This appears to occur in
sequence, rather than in synergism, as the effects of platelets are absent after 14 days
without mechanical loading. This proposed principle, however, does not show directly
what time point mechanical loading starts to stimulate repair. With respect to clinical
implications in humans, the authors suggest that these results support the use of
mobilization in AT rupture rehabilitation and that platelet injections can increase the
response of tendon cells to loading of the tendon.
Lyras et al (2009)145 examined the influence of PRP on angiogenesis during the early (i.e.
inflammatory and proliferative) phase of healing in 48 rabbits. The rabbits were
randomized to receive PRP (n=24) or a saline injection (n=24) during surgery in both of
their transected ATs. Six rabbits from each group were sacrificed at one, two, three, and
four weeks, respectively, at which time an immunohistochemical analysis was performed
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on the tendons. Microscopic images of the tendons were obtained and an angiogenesis
analysis was performed using an established technique. Vessel density (mean number of
vessels per mm2) was significantly higher in the PRP group (mean=495) than the control
group (mean=322) at one week (p<0.0001) and at two weeks (mean=1736 versus 309;
p<0.0001). At three and four weeks, the control group had significantly higher vessel
density than the PRP group (p<0.0001). These results suggest that PRP can significantly
increase the vascularity of injured ATs in the early stages of healing, corresponding to the
inflammatory and proliferative phases. Given that tendons are poorly vascularized
structures, an increase in vascularity could contribute to more substantial healing and
remodeling of the tendon. It is important to note that although these results demonstrate
increased vascularity, there was no biomechanical or functional evaluation of these
tendons. These results, therefore, do not have any functional implications.
In 2010, Lyras et al146 investigated the effect of PRP on transforming growth factor β1
(TGF-β1) expression during tendon healing in rabbits. The authors hypothesized that
PRP alters the tendon healing process by altering the expression of the multifunctional
growth factor TGF-β1. Expression of TGF-β1 was assessed by immunostaining the
specimens with anti-TGF-β1 primary antibody to which TGF-β1 would bind to. A total
of 48 rabbits (96 limbs) were randomized to receive a PRP injection or no injection upon
surgical transection of their AT. TGF-β1 levels were assessed at one, two, three, and four
weeks post-transection. The results indicated that the PRP group had significantly higher
expression of TGF-β1 at one and two weeks (p<0.0001), and the control group had
significantly higher TGF-β1 expression at three and four weeks (p<0.0001). In the
control group in this study, TGF-β1 expression progressively increased over the four
week period. Conversely, TGF-β1 expression progressively decreased in the PRP group.
Ultimately, these results suggest that PRP alters the temporal expression of TGF-β1. The
significance of this is not completely understood, but the authors suggest that further
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study of how various growth factor expression is altered after PRP injections could lead
to a more thorough understanding of how PRP affects the healing process.
Kaux et al (2012) studied the effects of PRP on the healing of surgically transected ATs
of 120 Sprague-Dawley rats. The rats received either a PRP injection (n=60) or a control
injection (n=60), defined as a “physiological solution”. It was not explicitly stated how
the rats were allocated into treatment or control groups. Injections were performed two
hours after the tendons had been surgically transected. Biomechanical and histological
analyses were performed at 5, 15, and 30 days post-injection. Biomechanical evaluation
was performed using a traction-compression testing machine, and values for ultimate
tensile strength (UTS) were normalized by accounting for the cross-sectional area of the
tissue. The UTS represents the amount of force applied to the tissue at its failure point.
Histological evaluation was accomplished by staining sections of the tendons and
subsequently obtaining photomicroscopic images which enabled the quantification of
collagen content. Additionally, tenocyte proliferation was assessed by quantitiative
reverse-transcription polymerase chain reaction (RT-PCR). The biomechanical results
showed that the UTS was higher in the PRP group than the control group at all time
points, with statistically significant differences at 15 and 30 days (p<0.05). There were no
obvious histological differences in tissue organization between groups. There was,
however, increased deposition of structured collagen fibres at day five in the PRP group
(p=0.03). Ultimately, these results suggest that PRP influences the early phase of tendon
healing from a histochemical standpoint, which results in stronger mechanical resistance
during later phases of healing.
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2.6.5.2
2.6.5.2.1

Human Trials
Operative Trials

Sanchez et al (2007) examined the effect of PRP injection and a platelet-rich fibrin matrix
(PRFM) scaffold application in 12 athletes who underwent open surgical repair of their
AT rupture. Six athletes received the PRP treatment and their outcomes were
retrospectively compared with six athletes who underwent open surgical repair with no
PRP augmentation. Identical surgical procedures were performed in each group, with the
addition of a PRP injection into tendon fibers after the tendon was sutured followed by a
PRFM application. The PRP treatment group experienced significantly earlier restoration
of functional range of motion (7 versus 11 weeks; p<0.05), earlier time to running (11
versus 17 weeks; p<0.05), and earlier time to return to normal training activities (14
versus 21 weeks; p<0.05). Additionally, the mean increase in cross-sectional area of the
operated tendon was significantly less in the PRP group than the control group (298% ±
90% versus 499% ± 91%, respectively; p=0.009). There were no re-ruptures in either
group. The authors concluded that the addition of PRP and PRFM scaffolding in open
suture repair of AT ruptures could provide opportunities for enhanced healing and
functional recovery, although a larger RCT is warranted to confirm these results
In a randomized, patient-blinded study, Schepull et al (2011)147 consecutively recruited
30 patients for PRP injection (n=16) or no injection (n=14) at the time of open surgical
repair of an AT rupture. All patients were operated on within five days of their injury.
The primary outcomes were the E-modulus (which describes the elastic property of a
tissue) at 7 weeks and the heel raise index at 52 weeks. There were no significant
differences in the E-modulus between groups at any time point. Furthermore, there was
no significant differences were found in the heel raise index at 52 weeks. The patientreported Achilles tendon rupture score (ATRS) was significantly lower (i.e. inferior

49

function) in the PRP group than the control group (78 versus 89; p=0.014) at 52 weeks.
There was one re-rupture in the PRP group who was lost to follow-up, and no reruptures
in the control group. The authors concluded that there was no clinical or functional
benefit to PRP treatment in AT surgical repair. One possible explanation for the lack of a
treatment effect is the fact that patients were immobilized in a plaster cast for seven
weeks post-surgery, as it has been demonstrated in animal studies that there is an
interplay between autologous platelet augmentation and early mechanical loading in AT
repair10. A weakness of this study is that there was no control injection, which prevented
blinding of the clinical investigators to the treatment group of the patients. Investigator
blinding could have been accomplished by having saline injections for the control group,
and masking the contents of all syringes with opaque tape.
De Carli et al (2015)148 alternately assigned 30 patients on a case-by-case basis to receive
PRP (n=15) or no PRP (n=15) during surgical repair of AT rupture. Liquid PRP and PRP
gel was applied at the suture site in the treatment group. All surgeries were performed
within three days of the rupture. Patient-reported outcome measures were assessed at 1, 3,
6, and 24 months and included the VISA-A, FAOS, and VAS. Functional outcome
measures were assessed at 6 months and included isokinetic strength assessment and
jumping capability assessment. MRI and ultrasound images were also obtained at six
months. The results of this study demonstrated that there was no statistically significant
differences in any of the patient-reported or functional outcome measures. Furthermore,
ultrasound and MRI revealed similar morphostructural findings in both groups with
respect to tendon integrity and structure. The authors concluded that, due to substantial
equivalence in structural and functional results between groups, there appears to be no
clinical benefit to the addition of PRP to surgical treatment of AT rupture. A weakness of
this study is the alternate assignment of patients to treatment or control groups, which
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enables investigators to deduce the allocation to grouping. Additionally, there was no
mention of whether or not patients were blinded to group allocation.

2.6.5.2.2

Non Operative Trials

In a retrospective comparative study, Kaniki et al (2014)8 compared the clinical and
functional outcomes of consecutively recruited patients (n=73) who received PRP
injections in the non-operative management of AT rupture to a historical control group
who solely underwent non-operative management (n=72). All injections were performed
within 14 days of rupture. The primary outcome was isokinetic strength ratio for plantar
flexion of the injured ankle to the uninjured ankle at one year and two years. Secondary
outcomes included ROM, calf circumference, Leppilahti score, and AOFAS score. The
mean isokinetic strength ratio at 30°/s for the PRP and non-PRP groups was 87.9%
(±19.6%) and 92.2% (±33.9%), respectively, at one year and 87.8% (±15.7%) and 91%
(±35.7%), respectively, at two years. At 60°/s, the isokinetic strength ratio between the
PRP and non-PRP groups was 90% (±23.3%) and 87.6% (±25.6%), respectively at one
year and 89.6% (±21.3%) and 84.8% (±21.1%), respectively, at two years. The mean
between-group differences were not statistically significant for any speed at any time
point. Furthermore, there were no statistically significant differences between groups for
any of the secondary outcomes. Two patients in the PRP group and three patients in the
control group experienced re-ruptures. Ultimately, these results suggest that there is no
measureable clinical or functional benefit from PRP in AT healing. A limitation of this
study is the timing of the PRP injections. Patients were injected up to 14 days postrupture, corresponding to the late proliferative (i.e. secondary) phase of tendon healing.
In the present study, we aimed to address this limitation by injecting patients in the late
inflammatory (i.e. primary) or early proliferative healing phase in hopes that the effects
of the PRP would be more pronounced in this phase.
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2.7

Summary

The AT is the most commonly ruptured tendon in the human body; occurring more often
in men and in individuals between 30 and 39 years of age. There is some evidence that
the incidence of AT rupture increases within the last two to three decades. AT ruptures
are more likely to occur during sporting activities, especially those that involve rapid,
eccentric, impact loading. Additionally, there are several documented risk factors that can
potentially predispose an individual to tendon rupture, but consensus is lacking amongst
researchers regarding the definitive contributions of these factors.
AT ruptures can be treated operatively or non-operatively, although the optimal treatment
remains controversial. Traditionally, operative treatment of AT rupture has been
associated with a lower re-rupture rate compared to non-operative treatment but also a
higher complication rate. However, there is evidence to suggest that the rehabilitation
protocol, not the initial treatment, has a significant influence on re-rupture rate.
Specifically, when an accelerated functional rehabilitation protocol is followed, rerupture rates are similar between patients treated operatively and non-operatively.
The effectiveness of PRP in the treatment of musculoskeletal injuries remains
controversial because studies evaluating its effectiveness use different preparation
methods, ultimately yielding a different PRP product with respect to the platelet
concentration, the presence or absence of leukocytes, and the need for a platelet activator.
Furthermore, this information is rarely documented, limiting the ability to make accurate
comparisons across studies.
Achilles tendon healing is a slow process that occurs in three overlapping phases: the
inflammatory phase; the proliferative phase; and the remodeling phase. The inflammatory
phase lasts approximately 24 to 48 hours and is characterized by the activation of
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platelets and neutrophils which leads to the release of bioactive factors that initiate the
healing response. Approximately three to five days after injury, the proliferative phase
begins whereby angiogenesis and collagen production increases. At approximately six
weeks, the remodeling phase begins which results in a gradual increase in type I collagen
synthesis. This phase can last for several years. Since platelets activation is generally the
most pronounced in the inflammatory phase, it is thought that PRP could have a more
pronounced effect if introduced to the ruptured tendon as early as possible, which
provides the rationale for the timing of the injections in this study.
The use of imaging (US and MRI) as a measure of outcome in tendon healing has been
attempted by researchers, although the criteria used to assess tendon healing differs from
trial to trial and the relative importance of each criteria to tendon healing has not been
established. Both US and MRI are well-suited to tendon evaluation, with MRI having the
advantages of a broader anatomic overview and excellent soft-tissue contrast and US
having the advantages of being more rapidly performed, more cost-effective, and the
ability to perform dynamic evaluations. Ultimately, it has been demonstrated that US and
MRI are grossly comparable with respect to sensitivity and specificity in the diagnosis of
tendon pathologies. To our knowledge, however, no studies have longitudinally evaluated
and attempted to quantify the healing AT using both US and MRI.
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Chapter 3

3

Objectives

3.1

Primary Objective

Our primary objective was to compare the radiological assessments of tendon integrity
and healing using ultrasound and magnetic resonance imaging between patients who
received two ACP® injections and patients who received two placebo injections in the
non-operative treatment of Achilles tendon ruptures.

3.2

Secondary Objectives

The secondary objective of this study was to compare the isokinetic strength scores,
Ankle-Hindfoot Scale (AOFAS) scores, Leppilahti scores, Achilles Tendon Total
Rupture (ATRS) scores, range of motion, and calf circumference between patients who
received two ACP® injections and patients who received two placebo injections in the
non-operative treatment of Achilles tendon ruptures.

3.3

Overall Study Objective

The ultimate objective of this study was to determine whether the results support
conducting a larger RCT. This thesis is based on the six-month outcomes for 20 patients.
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Chapter 4

4

Methods
4.1

Study Design

This study was a single-centre randomized trial where the patients and outcome assessors
were blind to group allocation. Patients (n=20) were consecutively recruited from the
Fowler Kennedy Sports Medicine Clinic upon referral from emergency rooms in London,
Ontario, Canada and surrounding areas. This study was approved by the institutional
Health Sciences Research Ethics Board at Western University (Appendix A).

4.2

Eligibility Criteria

Eligible patients had a complete rupture of the Achilles tendon that was confirmed by
diagnostic ultrasound within seven days of the initial injury, were able to speak and
understand the English language, were willing to follow the recommended rehabilitation
protocol, and were between the ages of 16 and 70 years. Patients were excluded if they
had previous injury to the Achilles tendon, significant ipsilateral injury (e.g. bone
fracture), open injury to the Achilles tendon, avulsion of the Achilles tendon from the
calcaneus, or fluoroquinolone-associated rupture. We excluded patients who were
pregnant, had any neurological or collagen or vascular disease (stroke, Ehlers-Danlos
syndrome, cerebral palsy), diabetic, or unable to tolerate magnetic resonance imaging
(MRI).
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4.3
4.3.1

Treatment & Rehabilitation Protocol
Acute Treatment

All patients were prescribed a removable below-knee orthosis with a 2 cm heel-lift upon
diagnosis of an Achilles tendon rupture. The heel-lift provided approximately 20 degrees
of plantar-flexion at the ankle joint, corresponding to the optimal position for healing of
the Achilles tendon fibres. Patients were instructed to remain non-weight-bearing in the
Aircast™ brace until six weeks post-injury during all activities of daily living with the
exception of bathing.

4.3.2

Intervention Protocol

Patients were randomized by computer to receive either Autologous Conditioned Plasma
(ACP®) or placebo (saline). All patients, including those in the placebo group, followed
an identical injection procedure with the exception of the contents of the injection.
Additionally, all patients had an extra vial of blood drawn (approximately 10 cc’s) to
obtain a complete blood count (CBC) analysis at the time of injection. The clinician
(KW), data collectors, and patients were blinded to group allocation. Blinding was
accomplished by having a third-party (nurse) perform the computer randomization and
prepare the injections. The injections were prepared in a private room where the contents
of the syringe were masked by opaque tape.

4.3.3

Autologous Conditioned Plasma (ACP®)

Approximately 10 cc’s of blood was drawn from each patient into an Arthrex ACP®
double-barrel syringe and spun in a table-top Rotafix 32A centrifuge (Figure 9) at 1500
rpm for five minutes. This process yielded a distinct three-layer distribution of blood
components (Figure 10). The double barrel syringe enables the extraction of only the top
plasma layer (platelet-rich) without significant contamination from the other two layers.
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The amount of plasma obtained from this method ranged from 3 to 4 cc’s. Approximately
0.25 cc’s of ACP® was transferred to a separate vial in order to undergo a platelet and
leukocyte quantification analysis.
Once the plasma had been isolated in the syringe and prepared for injection, the clinician
(KW) used palpation and ultrasound measurements to identify the location of the rupture
for injection. The injection site was sterilized and then anaesthetized with lidocaine (2%).
The ACP® was subsequently injected into the marked site. A second injection was
administered two weeks later following an identical protocol.

Figure 9 Centrifuge
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Figure 10 Three-layer ACP

4.3.4

Rehabilitation

Patients were advised to begin physiotherapy at four weeks post-injury, placing an
emphasis on active plantar/dorsi flexion to neutral, inversion/eversion below neutral,
modalities to control swelling, knee/hip exercises, non-weight-bearing cardiovascular
work, and hydrotherapy. From six to eight weeks, patients were advised to remove the
heel-lift from their Aircast™ boot and begin weight-bearing as-tolerated. Stretching and
resistance exercises, proprioceptive training, and cardiovascular training with weightbearing as-tolerated were also introduced in the protocol. During weeks eight through
twelve, patients were weaned off of the Aircast™ boot while using crutches as necessary,
then weaned off of the crutches. Progressive increases in strength, proprioception, and
range-of-motion (ROM) were also emphasized. After 12 weeks, patients were advised to
continue progressing with strength exercise, proprioception, and range-of-motion, while
also introducing plyometric training and sport-specific retraining if applicable.
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4.4

Primary Outcome – Healing

Healing was assessed through a series of ultrasounds and MRI’s. A single, blinded
radiologist (AS) interpreted all images and an ordinal estimation of the healing
percentage (i.e. 0 to 25%; 26 to 50%; 51 to 75%; 76 to 100%) of the tendon was provided
based on objective criteria within each image. These criteria, as well as the methods for
obtaining the images are listed below.

4.4.1

Ultrasound

Ultrasound images were obtained by an experienced musculoskeletal sonographer using a
Phillips IU22 machine with the linear L12-5 probe (Phillips, Amsterdam, Netherlands).
Patients laid prone with their feet hanging over the edge of the exam table in slight
dorsiflexion. Transmission gel was used to optimize image quality. Sagittal images were
obtained by aligning the long axis of the ultrasound probe with the long axis of the
Achilles tendon beginning at the tendon insertion, moving proximally to the
musculotendinous junction while simultaneously sweeping across the width of the tendon
mediolaterally to visualize the tendon’s full extent. Transverse evaluation was
accomplished by orienting the long axis of the transducer 90° to the long axis of the
Achilles tendon and sliding the probe from distal to proximal. Dynamic imaging
consisting of dorsi- and plantarflexion maneuvers while positioning the probe in the
sagittal plane was carried out in all patients at baseline and after 6 weeks. Colour Doppler
was applied in the sagittal and transverse planes in the vicinity of the tear to assess for
hyperemia.
Representative still images and cine clips on ultrasound were captured for review by a
musculoskeletal radiologist (AS) with over 20 years of experience. Specifically, the
radiologist (AS) quantified the length of the gap (average), presence of hyperemia on
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colour Doppler, antero-posterior diameter of the gastrocnemius (injured and contralateral
side), echogenicity of the gastrocnemius (isoechoic, hypoechoic, hyperechoic), location
of the tear (distance from the calcaneal tuberosity), background tendon quality (normal or
tendinosis), maximum tendon diameter remote from tear, and the presence of
calcification. At six weeks and onward, dynamic uniform motion of the tendon was also
evaluated. The main criteria factoring into the healing estimation for US are: the size or
presence of a gap; the degree of uniform motion on dynamic evaluation; and the
echogenicity and continuity of the tendon fibres.

4.4.2

MRI

MR images were obtained using a 1.5 T MRI scanner (CVMR, General Electric,
Milwaukee, USA) with phased array extremity coil. Patients laid supine on the MRI table
and then entered the MR tunnel. Images were obtained in the sagittal and axial planes
(see Appendix D for detailed description of imaging sequences). Similar to the ultrasound
protocol, these images were evaluated against objective criteria to ultimately yield a
percent-healing estimation. Specifically, the radiologist (AS) quantified the length of the
gap (average), signal intensity at the site of the tear relative to normal tendon signal (T1,
T2, inversion recovery), presence of altered tendon contour, shape of the tendon (circular
or ellipsoid), anterior margin of the tendon (concave or convex), maximum diameter of
tendon at tear site, presence of peritendinous edema (none, mild, moderate, severe),
gastrocnemius signal intensity (normal, mild fatty-infiltration, moderate fatty-infiltration,
marked fatty-infiltration), location of tear from calcaneal tuberosity, background tendon
quality (normal or tendinosis), and maximum tendon diameter remote from tear. The
main criteria factoring into the healing estimation for MRI are: the size or presence of a
gap; the T2 signal at the tear site; and the overall appearance and continuity of the
tendon.
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4.5
4.5.1

Secondary Outcomes
Isokinetic Strength

Strength was assessed using a Biodex Multi-Joint System 3 Dynamometer (Biodex
Medical, Shirley, NY) (Figure 11) at six months and one year post-injury. The patient
was seated with their hip flexed at 45° supported by a thigh rest with the thigh strapped
into place to prevent upper-leg involvement in the strength assessment. The knee was
flexed at approximately 30° so that the tibia and fibula were parallel to the floor. The
medial malleolus was aligned with the dynamometers axis-of-rotation and the foot was
fixed to the dynamometer footplate by two Velcro straps and a modified ankle strap.
Patients performed a set of reciprocal plantar and dorsiflexion contractions at three
different testing velocities (30°/s, 60°/s, and 240°/s) on both the injured and uninjured
ankle. A brief familiarization period was allotted prior to each new set of contractions.
There were four reciprocal contractions at 30°/s and 60°/s and ten at 240°/s. One minute
of rest was given between each test velocity. Peak torque (Nm) for plantar flexion and
dorsiflexion was calculated by averaging peak torques of individual contractions at each
velocity.
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Figure 11 Biodex Dynamometer

4.5.2

Range of Motion

Plantar flexion and dorsiflexion was measured by a graduate student using a standard
goniometer. The graduate student was trained prior to participant testing by a certified
athletic therapist. The patient sat at the edge of the examination table with their knees and
ankles positioned in a neutral position at approximately 90°. The axis of rotation was
immediately inferior to the lateral malleolus and the long axis of the fibula was used as
the fixed lever arm. The moving lever arm was aligned with the fifth metatarsal. The
patient was instructed to move into plantar and dorsiflexion and the lever arm was moved
accordingly to record the amount of movement in degrees relative to the neutral position.
Assessment of plantar- and dorsiflexion ROM has high intra-rater reliability using a
goniometer, however, there is little evidence to support high inter-rater reliability due to
differences in rater training, the positioning of the patients, and the landmarks used149.
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4.5.3

Calf Circumference

Calf circumference was measured in centimeters using a standard flexible tape measure.
Patients were seated at the edge of the examination table with their lower legs relaxed off
of the table. Measurements were taken approximately halfway between the patella and
the ankle joint at the largest muscle bulk in the gastrocnemius.

4.5.4

Leppilahti Score

The Leppilahti is a disease-specific and functional outcome measure that evaluates
patient ratings of pain, calf muscle weakness and stiffness, footwear restrictions, range of
motion, and progress satisfaction. Isokinetic strength data for patient plantar and
dorsiflexion (30°/s, 60°/s, and 240°/s) is incorporated in the traditional scoring of the
Leppilahti. This outcome measure was able to detect change in a similar sample of
patients in a previous trial at our center comparing operative to non-operative
management of AT rupture.

4.5.5

Ankle-Hindfoot Scale (AOFAS)

The AOFAS is an objective functional scale and a region-specific quality of life measure.
This questionnaire examined the patient’s function (seven items), alignment (one item)
and pain (one item) with a combination of subjective grading from the patient and
objective evaluation from the physician. Pain was rated by the patient and alignment was
objectively rated by the physician; functional questions were answered by both the
patient (four items) and the physician (three items). The AOFAS has demonstrated
concurrent validity150,151, criterion validity151, construct validity152, and test retest
reliability151 in patients with various foot and ankle disorders.
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4.5.6

Achilles Tendon Total Rupture Score (ATRS)

The ATRS is a self-administered instrument for measuring patient outcomes after
treatment for Achilles tendon rupture. There are ten items in the questionnaire that
assesses the patient’s limitations as a result of their symptomology (i.e. pain, stiffness,
etc.) and limitations in various physical activities (i.e. walking, running, climbing stairs,
etc.). For each item the patient was required to rate their limitations on a scale of 0
(severe limitations) to 10 (no limitations). The sum of all responses represented their
overall score out of 100. This outcome measure was originally in the Swedish
population153, however, it has demonstrated adequate validity, reliability, responsiveness,
and sensitivity in English-speaking populations as well154.
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4.6
Outcome
Measure
US

Timeline for Outcome Measures
0W

2W

4W

6W

8W

12 W

24 W

X

X

X

X

X

X

X

X

X

X

MRI

1Y

AOFAS

X

X

X

X

X

ATRS

X

X

X

X

X

X

X

X

X

Leppilahti

X

X

Strength

X

X

ROM

Abbreviations. W = weeks; Y = year; US = ultrasound; MRI = magnetic resonance
imaging; AOFAS = American Orthopedic Foot & Ankle Society; ATRS = Achilles
tendon rupture score; ROM = range of motion
Table 3 Timeline for all study outcome measures

4.7

Plan for Analysis

We used SPSS version 22 to perform all data analyses except weighted-kappa
calculations, for which we used MedCalc version 15.8. The demographic characteristics
of each group were presented using descriptive statistics; means and standard deviations
were used for continuous variables (e.g. age, height, weight) and proportions for nominal

65

variables (e.g. gender, affected foot, activity at onset). Because our sample is small, we
used non-parametric analyses to test for between-group differences for all outcome
measures. For the ordinal estimations of percent healing using US and MRI, we used the
Mann-Whitney U test to determine the mean rankings of healing for each group.
Additionally, a weighted-Kappa was used to measure the agreement between US and
MRI assessments at coinciding time points. For outcome measures with baseline
measurements (ATRS, AOFAS) we used the Mann-Whitney U test to determine the
median difference in the change scores between baseline and each time point for each
group. We used the Mann-Whitney U test when baseline data was not available to
determine the median difference in outcome measures at each time point. In all instances,
the independent variable was the treatment group and the dependent variable was the
ordinal or continuous outcome measure. Outcome data for continuous variables for each
group are presented as the median difference with the 25th to 75th interquartile range. A
p<0.05 was considered statistically significant. The intention-to-treat (ITT) principle was
followed for one patient who was randomized to the ACP® group but was given saline
injections due to technical difficulties with the centrifuge. We used last outcome carried
forward to fill any missing end point data. Specifically, one patient in the saline group
was missing his one-year range-of-motion, calf circumference, and isokinetic strength
assessments because he moved out of the province; these outcomes carried forward form
the six month assessment. He was able to complete all one-year patient-reported outcome
measures (AOFAS, ATRS, Leppilahti, return-to-sport) via the online data management
system (www.empowerhealthresearch.ca).
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Chapter 5

5

Results
5.1

Participant Flow

The flow of patients through each stage of the study is outlined in Figure 13. Between
February 2014 and June 2015, 74 patients were screened for eligibility. Of these, 42 did
not meet the eligibility criteria and eight declined to participate. We excluded patients if
they presented to clinic at their baseline visit greater than seven days post-rupture (n=39),
were greater than 70 years of age (n=2), or were diabetic (n=1). Patients declined to
participate in the study because they did not want to receive an injection (n=3) and
because they were unable to commit to all follow-up appointments (n=5). A protocol
deviation occurred for one patient who was greater than seven days post-rupture at the
baseline visit but was enrolled in the trial. A total of 24 patients were included in our
randomized control trial. One patient was lost to follow-up at the one year visit because
he moved to a different province.
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Assessed for Eligibility (n=74)

Ineligible (n=50)

Enrolled (n=24)

Included in this Thesis (n=20)

Age >70 (n=2)
Diabetes (n=1)
Rupture >7 days from initial visit (n=39)
Did not want injection (n=3)
Unable to commit to follow-up appointments (n=5)

ACP (n=10)

Non-ACP (n=10)

Baseline (n=10)

Baseline (n=10)

2 Weeks (n=10)

2 Weeks (n=10)

4 Weeks (n=10)

4 Weeks (n=10)

6 Weeks (n=10)

6 Weeks (n=10)

8 Weeks (n=10)

8 Weeks (n=10)
1 missing US (LOCF)

12 Weeks (n=10)

12 Weeks (n=10)
1 missing AOFAS, ATRS,
ROM (LOCF)

24 Weeks (n=10)

24 Weeks (n=10)

Included in Analysis (n=10)

Included in Analysis (n=10)
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Figure 12 Participant flow through the trial

5.2

Demographic Information

At the time of analysis, 20 patients had completed the study protocol to six months of
follow-up. Patient demographic characteristics were similar between groups (Table 4).

Characteristics

ACP® (n=10)

Non-ACP® (n=10)

8 (80)

8 (80)

Median Age (IQR), years

39.0 (29.0 to 61.0)

38.0 (33.0 to 46.0)

Median Height (IQR), cm

177.8 (171.4 to 181.6)

174.0 (165.1 to 180.7)

Median Weight (IQR), kg

80.7 (75.0 to 91.8)

87.0 (71.8 to 93.2)

Injured Achilles, n (%)
Right

5 (50)

3 (30)

Injured Achilles, n (%)
Dominant

6 (60)

6 (60)

10 (Sports)

10 (Sports)

Sex, n (%)
Male

Activity at injury, n (Sports
or ADL)

Abbreviations: IQR = Inter-quartile range; ADL = activities of daily living
Table 4 Patient demographics
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5.3

Injection Information

White blood cell (WBC) and platelet quantification was conducted on both blood and
ACP® samples from nine patients at baseline and at two weeks. One patient was missing
WBC and platelet quantification on the ACP® sample at baseline because there was an
insufficient amount of the sample to conduct the analysis (Table 5).

Time

Blood WBC
Count*
(mean ± SD)

Blood
Platelet
Count*
(mean ± SD)

ACP® WBC
Count*
(mean ± SD)

ACP®
Platelet
Count*
(mean ± SD)

Amount
Injected‡
(mean ± SD)

Baseline

7.7 (1.8)

215.1 (16.9)

0.9 (0.8)

390.7 (41.2)

3.2 (0.4)

2 Weeks

6.9 (1.6)

232.2 (32.9)

0.8 (1.0)

441.6 (76.3)

3.1 (0.2)

Abbreviations. WBC = white blood cell; ACP = Autologous Conditioned Plasma; SD =
standard deviation
*cell count x109/L
‡cubic centimeters (cc’s)
Table 5 White blood cell and platelet counts of patients' blood and ACP samples

5.3.1

“PAW” Classification

Based on the classification system proposed by DeLong et al (2012)7, our ACP® system
would be classified as “P2-Bβ”. “P2” represents a platelet concentration that is above
baseline and up to 750 x 109 platelets/L. “B” and “β” represent below baseline
concentrations of WBC and neutrophils, respectively.
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5.4

Location of Tendon Rupture

Tendon ruptures occurred at a mean of 5.2 cm (± SD 1.3 cm) from the calcaneal insertion
as measured by baseline US assessments.

5.5
5.5.1

Primary Outcome
Estimated Percent Healing

One patient in the non-ACP® group was missing eight week ultrasound data. There were
no statistically significant differences between groups in the estimated percent healing at
any time for US or MRI assessments. The mean rankings were higher in the ACP group
versus the non-ACP group at 4 weeks (11.0 versus 10.0), 8 weeks (11.2 versus 9.8), and
12 weeks (11.85 versus 9.15) for ultrasound assessments. The mean rankings were equal
at 24 weeks. The mean rankings were higher in the ACP group at 12 weeks (12.6 versus
8.4) and 24 weeks (11.4 versus 9.6) for MRI assessments. Figures 13-18 present the
number of patients in each group that correspond to each healing range for both US and
MRI at each time point.
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Figure 13 Estimated percent healing at two weeks post injection with ACP or saline
based on ultrasound imaging
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Figure 14 Estimated percent healing at four weeks post injection with ACP or saline
based on ultrasound imaging
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Figure 15 Estimated percent healing at six weeks post injection with ACP or saline based
on ultrasound imaging (left) and MRI (right)
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Figure 16 Estimated percent healing at eight weeks post injection with ACP or saline
based on ultrasound imaging
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Figure 17 Estimated percent healing at 12 weeks post injection with ACP or saline based
on ultrasound imaging (left) and MRI (right)
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Figure 18 Estimated percent healing at 24 weeks post injection with ACP or saline based
on ultrasound imaging (left) and MRI (right)

5.5.1.1
5.5.1.1.1

US and MRI Agreement
Estimated Percent Healing

The agreement between US and MRI ratings of healing was “fair” at 6 and 12 weeks, and
“poor” at 24 weeks (Table 6).
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Test

Agreement (95% CI)

Weighted Kappa

6 Weeks

12 Weeks

24 Weeks

0.20 (-0.06 to 0.46)

0.36 (0.03 to 0.68)

0.17 (-0.10 to 0.43)

Abbreviations. CI = confidence interval. Note: According to Altman (1999)155 (slightly
adapted from Landis & Koch (1977)156), agreement is classified as ‘poor’ if κ <0.20, ‘fair
if κ > 0.20 to 0.40, ‘moderate’ if κ > 0.40 to 0.60, ‘good’ if κ > 0.60 to 0.80, and ‘very
good’ if κ > 0.80 to 1.00.
Table 6 Ultrasound and MRI agreement on ordinal ratings of estimated percent healing at
6, 12, and 24 weeks

5.6
5.6.1

Secondary Outcomes
Patient-Reported Outcomes

There was one patient in the non-ACP® group who did not complete the 12 week
AOFAS and ATRS questionnaires. The ACP® group had higher median AOFAS change
scores at six weeks and higher median ATRS change scores at 12 and 24 weeks. There
was no significant difference in the median change scores from baseline at any time point
for the AOFAS or the ATRS outcome measures. Both groups had improved change
scores at each successive visit. There was a statistically significant difference in favor of
the ACP group at 24 weeks for the Leppilahti score (p=0.04) (Table 7).
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Time

Outcome

ACP®
Median (IQR)

Non-ACP®
Median (IQR)

p-value

AOFAS

32.0 (21.5 to 38.5) 29.0 (23.8 to 36.3)

0.80

ATRS

12.0 (5.5 to 22.8)

19.5 (10.5 to 32.0)

0.44

AOFAS

38.0 (26.0 to 56.3) 40.5 (37.0 to 50.5)

0.85

6 weeks

12 weeks
ATRS
AOFAS
24 weeks ATRS
Leppilahti

38.0 (15 to 47.5)

32.0 (19.3 to 40.3)

0.28

45.5 (38.3 to 60.0) 48.5 (36.8 to 55.3)

0.63

66.5 (48.0 to 78.0) 61.0 (37.5 to 80.0)

0.74

75.0 (61.3 to 80)

55.0 (42.5 to 71.3)

0.04

Abbreviations. ACP® = Autologous Conditioned Plasma; AOFAS = American
Orthopedic Foot and Ankle Society; ATRS = Achiles Tendon Total Rupture Score; IQR
= Interquartile range (25% to 75%)
Table 7 American Orthopedic Foot and Ankle Society score, Achilles Tendon Total
Rupture Score at 6, 12, and 24 weeks and Leppilahti score at 24 weeks post-rupture

5.6.2
5.6.2.1

Functional Outcomes
Range of Motion

One patient in the non-ACP® group was missing ROM data at 12 weeks. The ACP®
group had a lower median side-to-side deficit in plantar flexion at 6 and 24 weeks, and a
lower median side-to-side deficit in dorsiflexion at 12 and 24 weeks. There was a
statistically significant difference in the median side-to-side difference in dorsiflexion
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ROM at 12 and 24 weeks in favor of the ACP®. Additionally, the ACP® group had a
lower deficit in median calf circumference at 6 and 24 weeks. There were no statistically
significant differences in plantar flexion or calf circumference between groups at any
time point (Table 8).
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Time

6 weeks

12 weeks

24 weeks

Measurement

ACP® Median

Non-ACP® Median

p-value

(unit)

Difference* (IQR)

Difference* (IQR)

PF°

5.5 (-1.8 to 19.3)

13.5 (4.5 to 18.3)

0.35

DF°

5.0 (0.0 to 9.5)

5.0 (3.8 to 10.8)

0.48

CC (cm)

1.0 (0.8 to 3.3)

2.5 (2.0 to 3.0)

0.28

PF°

5.5 (0.5 to 7.0)

4.5 (3.8 to 9.8)

0.63

DF°

3.5 (-0.3 to 5.0)

6.0 (5.0 to 8.0)

<0.01

CC (cm)

1.5 (-0.3 to 2.5)

1.5 (0.8 to 4.0)

0.63

PF°

2.0 (-1.0 to 4.5)

5.0 (2.0 to 8.3)

0.16

DF°

1.5 (-2.8 to 3.3)

6.5 (4.5 to 7.5)

<0.01

CC (cm)

1.5 (1.0 to 2.0)

2.0 (0.8 to 2.0)

0.91

Abbreviations. ACP® = Autologous Conditioned Plasma; PF = plantar flexion; DF =
dorsiflexion; CC = calf circumference; cm = centimeters; IQR = Interquartile range (25%
to 75%)
Table 8 Range of motion and calf circumference measurements at 6, 12, and 24 weeks
post-rupture
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5.6.2.2

Isokinetic Plantar Flexion Strength

There were no statistically significant differences between groups at any speed at 24
weeks post-rupture for the median strength ratio of the injured to uninjured Achilles, as
measured by the peak torque at each speed. The ACP® group had higher strength ratios
at 30°/s and 240 °/s (Table 9).

Speed

ACP® Median Strength Ratio

Non-ACP® Median Strength Ratio

p-value

(°/s)

% (IQR)

% (IQR)

30

75 (55.8 to 83.8)

71.5 (57.5 to 90.5)

0.97

60

70.5 (62.5 to 85.0)

73.0 (58.5 to 91.0)

0.85

240

90.0 (70.3 to 106.3)

84.5 (61.8 to 93.8)

0.25

Abbreviations. ACP® = Autologous Conditioned Plasma; IQR = 25% to 75%
Interquartile range
Table 9 Isokinetic strength ratio of the injured to uninjured Achilles at 24 weeks postrupture

5.7

Re-Ruptures and Adverse Events

There were no re-ruptures or adverse events for any patients in either group.
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6

Discussion

The purpose of this thesis was to compare the six month results for AT rupture patients
who were randomized to receive ACP® or saline injections at baseline (i.e. within seven
days) and two weeks post-rupture. Tendon healing was assessed using a longitudinal
series of US and MR images. Functional assessments included isokinetic strength and
ROM. Quality-of-life, pain, calf circumference, and subjective function was also
assessed. We found a statistically significant difference in favor of the ACP® group at 24
weeks for the Leppilahti score; there were no other significant differences between
groups at any time point for any other outcome measures. However, it should be noted
that our study was not powered to detect statistically significant differences. The aim of
this study was not to make clinical recommendations but rather to determine whether a
larger RCT is warranted.
Slow tissue turnover and regeneration in the AT results in a lengthy return of normal
function for patients with AT rupture. It has been demonstrated that non-operative
management of AT ruptures can yield comparable results with respect to function and rerupture rates to operative management when early mobilization (i.e. accelerated
functional rehabilitation) is employed4,5. The use of PRP to augment non-operative
treatment to improve healing and function is a sound theory from a physiological
perspective, although clinical benefits have yet to be conclusively demonstrated.
In 2014, Kaniki et al8 prospectively recruited patients (n=73) with AT ruptures and
injected them with ACP® within 14 days post-rupture, followed by a second injection
two weeks later. The clinical and functional outcomes of these patients were compared to
a retrospective cohort of non-operatively treated patients who did not receive ACP®.
There were no significant differences between the ACP® group and the historical control
group for isokinetic strength, ROM, or Leppilahti scores. One potential explanation for
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the lack of a treatment effect is that the injection period for patients in the ACP® group
corresponded to the mid- to late-proliferative (or reparative) phase of tendon healing
rather than the inflammatory phase of tendon healing. A significant characteristic of the
inflammatory phase of tendon healing is the activation of platelets at the site of
injury14,15. It was therefore hypothesized that ACP® injection during this early phase of
healing may have a more pronounced effect.
Our results demonstrate slightly more favorable assessments of healing in the ACP®
group at 4, 8, and 12 weeks on US and at 12 and 24 weeks on MRI. Furthermore, the
secondary outcomes in our study tended to favor the ACP® group over the non-ACP®
group: the median ATRS was higher at 12 and 24 weeks; the median Leppilahti score
was significantly higher at 24 weeks; the median side-to-side ROM differences were
smaller in plantar flexion at 6 and 24 weeks and in dorsiflexion at 12 and 24 weeks; and
the isokinetic strength ratio was larger at 30°/s and 240°/s.
One of the issues in the published literature that has made it difficult to draw definitive
conclusions about the effectiveness of PRP is that most studies do not report the
concentration of the components of the PRP used or the preparation method. Without
accurate documentation of the concentration of platelets, the manner of platelet
activation, and the presence or absence of WBCs the ability to truly contextualize study
results is limited7. DeLong et al (2012)7recently provided a means to classify solutions of
PRP (Figure 8). According to this classification system, the PRP samples prepared for
this study (i.e. ACP®) is “P2-Bβ” which means that the concentration of platelets is
greater than baseline but less than 750x109 /L (P2), the WBC concentration is below
baseline (B), and the neutrophil concentration is below baseline (β). A sample of PRP
that is too concentrated in platelets (i.e. >1800x109) can potentially have a toxic effect,
resulting in cellular apoptosis, growth factor receptor downregulation, and receptor
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desensitization, which ultimately may result in a paradoxical inhibitory effect157,158. PRP
samples above baseline and less than 750x109 /L have produced favorable results in
several studies12,159–165. The presence of WBC and neutrophils above baseline levels in
PRP samples has been linked to deleterious effects during tissue regeneration166–172, thus
our preparation method sought to avoid this potential issue by limiting their presence in
our samples.
Several studies have described the US or MRI features of an acutely ruptured or healing
Achilles tendon56,61,81,88,89, but none have used imaging to provide an overall estimation
of healing in the tendon. Furthermore, no other study has evaluated the tendon during the
different phases of tendon healing: Hollenberg et al61 described the US appearance of
ruptured ATs treated non-operatively within 48 hours of rupture and again at
approximately two years; Möller et al81 described and evaluated the healing AT following
surgery using US and MRI after 6, 12, and 24 weeks; Karjalainen et al88 evaluated the AT
3, 6, 12, and 24 weeks post-surgery using MRI. Our study evaluates the non-operatively
treated AT within seven days of rupture (inflammatory phase), and at 2 (proliferative
phase), 4 (proliferative phase), 6 (proliferative/remodeling phase), 8 (remodeling phase),
12 (remodeling phase), and 24 (remodeling phase) weeks post-rupture, ultimately
spanning all phases of the healing process.
Physiologically, the inflammatory phase is characterized by fluid infiltration causing
edema and subsequent activation of platelets and inflammatory cells13–15. On US
imaging, the fluid infiltration can be seen as an anechoic area located at or near the
rupture site. Additionally, there was marked loss in the normal fibrillar architecture of the
tendon (Figure 19). During the proliferative or reparative phase, tendon fibroblasts have
begun collagen synthesis and deposition into the wound site14,15. On US, collagen and
other extracelluar matrix components (collectively termed ‘granulation tissue’) appeared
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echogenic (i.e. bright) relative to the tendon (Figure 20). Similarly, on most MR
sequences, granulation tissue appears as increased signal intensity relative to the normal
tendon (Figure 21). The remodeling phase is characterized by the transformation of
granulation tissue to fibrous tissue, and again to scar-like tissue with high tensile
strength14,15. There is decreased cellularity and fluid presence at and around the injury
site. Scar tissue appeared hypoechoic to the surrounding tissue on US (Figure 22), and
hypointense on MRI (Figure 23). Disruption of the normal fibrillar architecture was
evident at 24 weeks post-rupture is a well-documented finding on US as described in
previous studies56,61,81Additionally, tendon thickening is evident on both US and MRI
also described in previous studies61,81,88,89.

86

T
T

*

Proximal

Long Axis

Figure 19 Baseline US of an acute Achilles tendon rupture (inflammatory phase). Long
axis view at the rupture site shows discontinuity of tendon fibres (T) with a gap (arrows
demarcate proximal and distal ends of the torn fibres) and a small anachoic fluid
collection (*) likely related to a hematoma. The Torn tendon fibres are hypoechoic,
mildly redundant and show loss of the normal fibrillar pattern
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Figure 20 Ultrasound image at six weeks (proliferative phase) in the same patient as
Figure 19. The previous anechoic fluid collection at the tear site has resorbed. A
prominent gap is evident at the site of the tear (arrows) filled with echogenic tissue (*)
which may correspond to granulation tissue. The tendon fibres adjacent to the tear are
thickened, disorganized and hypoechoic, potentially corresponding to persistent edema
and/or fibrous tissue
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Figure 21 MR image at six weeks (same patient). Sagittal fast inversion recovery image
(water weighted) shows a complete tear of the Achilles tendon with a residual gap at the
site of the tear (arrow) marked by increased signal intensity. Increased fluid manifested
by high signal intensity likely corresponding to extensive edema is present, most
conspicuous within the proximal aspect of the tendon (*).
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Figure 22 Ultrasound image at 24 weeks (late remodeling phase). Panorama long axis
ultrasound. The Achilles tendon (T) is thickened, hypoechoic with mild redundancy, loss
of the normal fibrillar pattern and disorganization of the tendon fibres, likely reflecting
post-traumatic scarring due to extensive background microtearing. There is slightly
increased signal at the site of previous discrete tear (arrows), without a residual gap
evident.
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Figure 23 MR image at 24 weeks (late remodeling phase). Sagittal fast inversion
recovery (water weighted). The previous gap is even more inconspicuous filled with
hypointense/dark tissue (*), likely corresponding to fibrous tissue. The tendon remains
thickened and abnormal
Ruptures of the AT occurred at a mean of 5.2 cm from the calcaneal insertion. Similarly,
Karjalainen et al88 and Hollenberg et al61 reported rupture sites at a mean of 5.9 cm and 6
cm from the calcaneal insertion, respectively. In a cadaveric study, Carr et al173 reported
that there is an area of low vascularity most prominent between 2 and 4 cm from the
calcaneal insertion. In our series, few patients had ruptures below this region and
therefore our results are in accordance with Schmidt et al174 and Karjalainen et al88 who
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stated that the area of poor vascularization and the rupture site may not necessarily be
correlated.
The agreement between US and MRI in our study at coinciding time points was
considered “fair” at 6 and 12 weeks (κ=0.20 and κ=0.36, respectively) and “poor” at 24
weeks (κ=0.17) according to the guidelines proposed by Altman (1999)155. This
agreement was considerably lower than the agreement reported by Connell et al94
(κ=0.52) in the MR and US evaluation of hamstring tears after six weeks. The most likely
explanation for poor agreement is our small sample size. Discrepant assessments of
healing between MRI and US have a pronounced effect on a small sample size compared
to a large sample size, especially in cases of extreme disagreement (i.e. ratings that differ
by two or more ordinal categories on a four category scale). Another potential
explanation is that we injected patients with either ACP® or saline, ultimately increasing
the amount of fluid at the injury site. This would likely present similarly to fluid/edema
on both MRI and US. Fluid is easier to distinguish from fibrous tissue on MRI than US.
On US both fluid and fibrous tissue appear hypoechoic, making distinction between the
two sometimes difficult. On MR however, fluid or edema appears as increased signal
intensity whereas fibrous tissue would appear as low signal intensity relative to the
healthy tendon. It has been shown that edema can be present in healing ATs up to six
months post-rupture81, therefore a discrepancy between US and MRI as a result of
distinguishing fluid from fibrous tissue could have occurred at all time points in our
study.

6.1

Study Strengths

Strengths of our study include the randomization of patients to intervention and control
groups, reducing the chance of selection bias. We were also able to blind the patient,
clinician, radiologist and outcome assessor to group allocation, reducing expectation and
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performance biases. We also only lost one patient to follow up (5%) and only two
patients had missing or incomplete data (10%). To our knowledge, our study is the first
RCT for PRP in the non-operative management of AT ruptures. Additionally, our study is
the first to attempt to quantify healing based on US and MR imaging.

6.2

Study Limitations

Our study was limited by a small sample size that limited our power to detect a
statistically significant treatment effect. Although we were aware we would be
underpowered, the small sample size led to a non-parametric distribution of data with
prevented us from performing parametric statistical analyses.
Our primary outcome was not a valid or reliable outcome measure, as we are the first to
attempt to quantify tendon healing based on imaging. Although there are objective
criteria that are evaluated within each tendon image, the overall estimation of percenthealing is subjective to the radiologist interpreting the image. Furthermore, the
radiologist was not blinded to the time-point of each image post-rupture, so it is possible
that there was an observational bias whereby the number of weeks post-rupture could
have influenced the healing rating. However, the radiologist was blinded to group
allocation so any observational biases would have been equal between groups and thus
should not have had a directional influence on the results.

7

Conclusion

This study compared the healing and function in non-operatively treated AT rupture
patients receiving either ACP® (n=10) or saline (n=10) injections. The findings in this
study are underpowered but there is sufficient evidence to suggest moving forward with a
larger RCT for early ACP® injections.
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7.1

Directions for Future Research

A. We will continue data collection for one-year functional (isokinetic strength,
ROM) and patient-reported (AOFAS, ATRS, Leppilahti) outcomes for all
remaining patients.
B. Further study into the use of different classifications of PRP (i.e. different
concentration of platelets, different method of platelet activation) to determine if
this will yield more favorable results.
C. Further study into whether certain features of AT imaging are predictive of, or
correlated to clinical or functional outcomes
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